_id,drug,structure,transporter,species,geneName,geneId,type,place,method,experimentalSystem,dose,route,substanceMeasured,concomitant,time,comment,parameterType,parameter,value,units,reference,source,sourceLink,year,TransporterInfo_id,fullname,structurelink
ISTE070327,Zosuquidar2,C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,0.024,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070328,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Colchicine,,,,IC50,IC50,0.027,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097567,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.038,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069000,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,0.04,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097857,Elacridar Hydrochloride,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC.Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.04,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070329,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Vinblastine1,,,,IC50,IC50,0.043,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070330,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,0.055,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070331,Zosuquidar2,C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,Abacavir,,,,IC50,IC50,0.07,ŒºM,"Shaik, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069002,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,0.1,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070332,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.1,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070333,Elacridar,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.1,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070334,Gpv062,O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCC(O)(c2ccccc2)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.1,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070335,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Rhodamine 123,,,,IC50,IC50,0.1,ŒºM,"Griffin, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070336,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.1,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070337,Zosuquidar2,C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.1,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070338,Valspodar2,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,0.11,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097858,Valspodar2,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.11,ŒºM,"Wandel, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097859,Selamectin,CO[C@H]1C[C@H](O[C@@H]2/C(C)=C/C[C@@H]3C[C@@H](C[C@]4(CC[C@H](C)[C@@H](C5CCCCC5)O4)O3)OC(=O)[C@@H]3C=C(C)/C(=N/O)[C@H]4OC/C(=C\C=C\[C@@H]2C)[C@@]34O)O[C@@H](C)[C@@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Rhodamine 123,,,,Ki,Ki,0.12,ŒºM,"Griffin, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069005,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.3-3 uM,,Seletalisib,[Seletalisib],,compared to concomitant drug alone,IC50,IC50,0.13,uM,DOI:10.1016/j.ejps.2019.105122   ISSN:09280987   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:105122   VOLUME:142,Literature,http://dx.doi.org/10.1016/j.ejps.2019.105122,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097568,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.3-3 uM,,Seletalisib,[Seletalisib],,compared to concomitant drug alone,Ki,Ki,0.13,uM,DOI:10.1016/j.ejps.2019.105122   ISSN:09280987   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:105122   VOLUME:142,Literature,http://dx.doi.org/10.1016/j.ejps.2019.105122,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069007,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,0.15,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069009,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,0.15,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069010,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-6 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,0.15,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073222,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,0.16,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069013,Ivacaftor,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,,,,IC50,IC50,0.17,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 203188/S-000 Part 03, page:34 PDF 10144k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097860,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,0.18,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069015,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,0.2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069017,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],10 min,,IC50,IC50,0.2,uM,DOI:10.1111/j.13497006.2009.01213.x   JOURNAL:Cancer Science   PAGES:1701   VOLUME:100,Literature,http://dx.doi.org/10.1111/j.1349-7006.2009.01213.x,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070339,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.2,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070340,Tariquidar,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,KBV1 cells,,,Calcein AM,,,,IC50,IC50,0.2,ŒºM,"Obreque-Balboa, 2016",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097861,Elacridar,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing Kb-V1 cells,,,Calcein AM,,,,Ki,Ki,0.2,ŒºM,"Puentes, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097862,Tariquidar,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing Kb-V1 cells,,,Calcein AM,,,,Ki,Ki,0.2,ŒºM,"Puentes, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070341,SDZ 280-446,CC[C@H](C)[C@H]1C(=O)NCC(=O)N([C@H](C(=O)N[C@H](C(=O)O[C@H](C(=O)N2CCCC[C@H]2C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1C)[C@@H](C)CC)C)CC(=O)OC(C)(C)C)C)C(C)C)C(C)C)C)C)CC3=CC=C(C=C3)OC)C(C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,IC50,IC50,0.22,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097569,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,SH-SY-5Y cells,<=7 uM,,Hoechst 33342,[Hoechst 33342],40 min,,Ki,Ki,0.24,uM,DOI:10.1016/j.toxlet.2015.04.005   ISSN:03784274   JOURNAL:Toxicology Letters   PAGES:189   VOLUME:235,Literature,http://dx.doi.org/10.1016/j.toxlet.2015.04.005,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069018,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,0.247,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073225,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,0.25,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069022,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,SH-SY-5Y cells,<=7 uM,,Hoechst 33342,[Hoechst 33342],40 min,,IC50,IC50,0.27,uM,DOI:10.1016/j.toxlet.2015.04.005   ISSN:03784274   JOURNAL:Toxicology Letters   PAGES:189   VOLUME:235,Literature,http://dx.doi.org/10.1016/j.toxlet.2015.04.005,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097570,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.29,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097572,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.29,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097573,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.29,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070342,Norverapamil,CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,0.3,ŒºM,"Pauli-Magnus, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097574,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,0.3,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097576,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocytes cells,,,Rhodamine 123,[Rhodamine 123],,,Ki,Ki,0.3,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097577,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",,,[3H]-Pitavastatin,[Pitavastatin Calcium],,,Ki,Ki,0.33,uM,DOI:10.1124/dmd.106.009290   JOURNAL:Drug Metabolism and Disposition   PAGES:1229   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.106.009290,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097863,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.35,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069023,Telmisartan,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388/ DX cells, recombinant",0-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,0.38,uM,DOI:10.1002/bdd.699   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:150   VOLUME:31,Literature,http://dx.doi.org/10.1002/bdd.699,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097864,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.39,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069026,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK (NBL-2) cells, recombinant",0-10 uM,,Calcein AM,[Calcein acetomethoxy ester],30 min,,IC50,IC50,0.4,uM,DOI:10.1016/j.bbrc.2006.05.058   JOURNAL:Biochemical and Biophysical Research Communications   PAGES:45   VOLUME:346,Literature,http://dx.doi.org/10.1016/j.bbrc.2006.05.058,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069030,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,0.4,uM,DOI:10.1124/dmd.105.007377   JOURNAL:Drug Metabolism and Disposition   PAGES:203   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.007377,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070344,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,Rhodamine 123,,,,IC50,IC50,0.4,ŒºM,"Lespine, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070345,Valspodar2,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,IC50,IC50,0.41,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069032,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,0.43,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069034,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,0.43,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069035,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,0.43,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097583,Mefloquine Hydrochloride,Cl.O[C@@H]([C@@H]1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.43,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097865,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.43,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097585,Propafenone Hydrochloride,Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.44,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097866,Elacridar (GF120918)2,COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,0.44,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069038,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,0.45,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069039,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,0.45,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097852,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.01-0.30 umol/L,,Verapamil Hydrochloride,[Verapamil Hydrochloride],2 h,,Ki,Ki,0.45,umol/L,DOI:10.1124/dmd.112.049577   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:683   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.049577,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097867,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.46,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069040,Ponatinib Hydrochloride,Cl.CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.0165-12 uM,,Digoxin,[Digoxin],,concentration dependent inhibition,IC50,IC50,0.49,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 203469/S-000 Part 04, page:14 PDF 2491k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070346,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.5,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070347,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.5,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070348,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,0.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070349,Rhodamine 123,COC(=O)C1=CC=CC=C1C2=C3C=CC(=[NH2+])C=C3OC4=C2C=CC(=C4)N.[Cl-],MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,0.5,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070350,Valspodar2,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.5,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070351,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Calcein AM,,,,IC50,IC50,0.5,ŒºM,"Pellicani, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069042,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,0.57,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069043,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,0.57,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069045,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,0.6,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070352,Clofazimine,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,0.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070353,Gpv005,O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCCCC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.6,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069048,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,0.62,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069049,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,0.62,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097588,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",12.5-25 uM,,Rivaroxaban,[Rivaroxaban],,competitive inhibition,Ki,Ki,0.68,uM,DOI:10.1124/dmd.116.073890   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:260   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073890,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097590,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.69,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070354,Cyclosporine,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.7,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070355,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing L5178 cells,,,Rhodamine 123,,,,IC50,IC50,0.7,ŒºM,"Broccatelli, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070356,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.7,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070357,Niguldipine,CC1=C(C(C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 exressing CCRF-cEM/VCR 1000 cells,,,Daunorubicin,,,,IC50,IC50,0.7,ŒºM,"Jabeen, 2012",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069054,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,5-Thio-tetramethylrosamine,[Thio-tetramethylrosamine],,,IC50,IC50,0.75,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069056,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,0.8,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070358,Aripiprazole,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing L5178 cells,,,Rhodamine 123,,,,IC50,IC50,0.8,ŒºM,"Broccatelli, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070359,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,0.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070360,Wk-X-50,O=C(Nc1ccc(CCN2CCc3ccccc3C2)cc1)Nc1ccccc1NC(=O)c1cnc2ccccc2c1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,0.8,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073229,Quetiapine Fumarate,OC(=O)\C=C\C(O)=O.OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-250 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,0.8,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097853,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.01-0.10 umol/L,,Loperamide Hydrochloride,[Loperamide Hydrochloride],2 h,,Ki,Ki,0.82,umol/L,DOI:10.1124/dmd.112.049577   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:683   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.049577,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069060,Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,0.83,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069061,Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,0.83,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069064,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,L-MDR1 cells,,,Loperamide,[Loperamide Hydrochloride],,,IC50,IC50,0.84,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021923/S-000, page:47 PDF 5152k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069066,Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-100 uM,,Quinidine,[Quinidine Sulfate],20-30 min,,IC50,IC50,0.84,uM,DOI:10.1007/s1331811469   JOURNAL:European Journal of Drug Metabolism and Pharmacokinetics   PAGES:115   VOLUME:36,Literature,http://dx.doi.org/10.1007/s13318-011-0046-9,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070299,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,L-MDR1 cells,,,Loperamide,[Loperamide Hydrochloride],,,IC50,IC50,0.84,umol/L,"EMA approval document: Scientific Discussion, page:21 PDF 389k",EMA approval document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097592,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,0.88,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097868,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,0.88,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070361,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Doxorubicin-resistant A2780 adr cells,,,Calcein AM,,,,IC50,IC50,0.9,ŒºM,"Juvale, 2013",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070362,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,0.9,ŒºM,"Kohler, 2015",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070363,"Lsn335984, 42",O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(Cl)Cl)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK2 cells,,,Calcein AM,,,,IC50,IC50,0.9,ŒºM,"Gannon, 2009",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070364,Norverapamil,CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,IC50,IC50,0.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070365,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,0.95,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097854,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.01-0.30 umol/L,,Loperamide Hydrochloride,[Loperamide Hydrochloride],2 h,,Ki,Ki,0.96,umol/L,DOI:10.1124/dmd.112.049577   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:683   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.049577,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070300,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",0.01-3000 uM,,Vincristine,[Vincristine Sulfate],,,IC50,IC50,0.97,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022425/S-000 Part 03, page:7 PDF 4017k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097594,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,0.97,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097597,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,0.97,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097599,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,0.97,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097869,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,0.97,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069071,Loperamide Hydrochloride,Cl.CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069073,Loperamide Hydrochloride,Cl.CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069075,Lurasidone Hydrochloride,Cl.[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",1 to 10 uM,,Digoxin,[Digoxin],,,IC50,IC50,1,uM,"EMA approval document: Assessment Report EMA/113836/2014; EMEA/H/C/002713/0000, page:35 PDF 2824k",EMA approval document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069076,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],2 h,,IC50,IC50,1,uM,"EMA approval document: Public Assessment Report EMA/CHMP/525204/2018; EMEA/H/C/004030/0000, page:50 PDF 3885k",EMA approval document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069077,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069078,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069082,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069083,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070366,(+)-devapamil,CC(C)[C@@](CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,1,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070367,Clofazimine,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070368,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097601,Tamoxifen Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(C1=CC=CC=C1)=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388 VMDR C0.4 cells, recombinant",0-100 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],60 min,,Ki,Ki,1,uM,JOURNAL:Biochimica et Biophysica Acta  Molecular Basis of Disease   PAGES:8   VOLUME:1316,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069085,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,1.03,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097604,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,1.09,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069088,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1.1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069090,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1.1,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070369,Clofazimine,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,1.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069092,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,1.12,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069098,Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-30 uM,,[3H]-digoxin,[Digoxin],120 min,,IC50,IC50,1.2,uM,DOI:10.1002/bdd.1801   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:304   VOLUME:33,Literature,http://dx.doi.org/10.1002/bdd.1801,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069105,Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.2-400 uM,,[3H]-Mitoxantrone,[Mitoxantrone Hydrochloride],120 min,,IC50,IC50,1.2,uM,DOI:10.1007/s00280910390   JOURNAL:Cancer Chemotherapy and Pharmacology   PAGES:335   VOLUME:65,Literature,http://dx.doi.org/10.1007/s00280-009-1039-0,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069106,Vorapaxar Sulfate,OS(O)(=O)=O.[H][C@@]12C[C@@H](CC[C@@]1([H])[C@H](\C=C\C1=CC=C(C=N1)C1=CC=CC(F)=C1)[C@]1([H])[C@@H](C)OC(=O)[C@]1([H])C2)NC(=O)OCC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.2,uM,"FDA approval package document: Pharmacology Review 204886/S-000 Part 03, page:15 PDF 455k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069107,Vorapaxar Sulfate,OS(O)(=O)=O.[H][C@@]12C[C@@H](CC[C@@]1([H])[C@H](\C=C\C1=CC=C(C=N1)C1=CC=CC(F)=C1)[C@]1([H])[C@@H](C)OC(=O)[C@]1([H])C2)NC(=O)OCC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.2,uM,"FDA approval package document: Pharmacology Review 204886/S-000 Part 06, page:24 PDF 15689k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070371,Chloropromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,1.2,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070372,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,1.2,ŒºM,"Krapf, 2017",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070373,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.2,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070374,Mibefradil,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.2,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073230,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.2,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073232,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],,,IC50,IC50 BA/AB,1.2,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073234,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.2,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073236,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.2,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073238,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,1.2,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097606,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,[14C]-Erythromycin,[Erythromycin],30 min,,Ki,Ki,1.23,uM,DOI:10.1016/j.ijpharm.2010.05.027   JOURNAL:International Journal of Pharmacology   PAGES:114   VOLUME:395,Literature,http://dx.doi.org/10.1016/j.ijpharm.2010.05.027,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097608,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,[14C]-Erythromycin,[Erythromycin],30 min,,Ki,Ki,1.23,uM,DOI:10.1016/j.ijpharm.2010.05.027   JOURNAL:International Journal of Pharmacology   PAGES:114   VOLUME:395,Literature,http://dx.doi.org/10.1016/j.ijpharm.2010.05.027,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097609,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,[14C]-Erythromycin,[Erythromycin],30 min,,Ki,Ki,1.23,uM,DOI:10.1016/j.ijpharm.2010.05.027   JOURNAL:International Journal of Pharmacology   PAGES:114   VOLUME:395,Literature,http://dx.doi.org/10.1016/j.ijpharm.2010.05.027,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069108,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,L-MDR1 cells,,,Dipyridamole,[Dipyridamole],,,IC50,IC50,1.24,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021923/S-000, page:47 PDF 5152k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070301,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,L-MDR1 cells,,,Dipyridamole,[Dipyridamole],,,IC50,IC50,1.24,umol/L,"EMA approval document: Scientific Discussion, page:21 PDF 389k",EMA approval document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070375,Desethylamiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCNCC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,1.27,ŒºM,"Kakumoto, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069112,Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,1.3,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069115,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,1.3,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069117,Niclosamide,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)N(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,1.3,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070377,Astemizole,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,1.3,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070378,Astemizole,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,1.3,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070379,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.3,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070380,Sirolimus,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Rhodamine 123,,,,IC50,IC50,1.3,ŒºM,"Wacher, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073241,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.3,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097610,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],,,Ki,Ki,1.3,uM,DOI:10.1111/j.13497006.2010.01539.x   JOURNAL:Cancer Science   PAGES:1493   VOLUME:101,Literature,http://dx.doi.org/10.1111/j.1349-7006.2010.01539.x,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097870,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,1.3,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070381,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,1.34,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070382,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Colchicine,,,,IC50,IC50,1.36,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097871,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,1.38,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069119,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-MDR-G185 cells, recombinant",,,Vanadate,[Vanadate],,,IC50,IC50,1.4,uM,DOI:10.1128/AAC.46.1.160165.2002   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:160   VOLUME:46,Literature,http://dx.doi.org/10.1128/AAC.46.1.160-165.2002,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069123,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,1.4,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069128,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-50 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,1.4,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:1080   VOLUME:29,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069137,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,1.4,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070383,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,1.4,ŒºM,"Klinkhammer, 2009",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070384,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,1.4,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070385,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,1.4,ŒºM,"Muller, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070387,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,1.4,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070388,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected NIH3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,1.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070389,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,1.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070390,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.4,ŒºM,"Wandel, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070391,Nelfinavir,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Daunorubicin,,,,IC50,IC50,1.4,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070392,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,1.4,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073242,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50 BA/AB,1.4,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:895   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073244,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.4,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073246,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,1.4,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073249,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,1.4,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097612,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,SH-SY-5Y cells,<=10 uM,,Hoechst 33342,[Hoechst 33342],40 min,,Ki,Ki,1.42,uM,DOI:10.1016/j.toxlet.2015.04.005   ISSN:03784274   JOURNAL:Toxicology Letters   PAGES:189   VOLUME:235,Literature,http://dx.doi.org/10.1016/j.toxlet.2015.04.005,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069140,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-6 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,1.45,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069145,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HL-60/ VCR cells,,,Daunorubicin,[Daunorubicin Hydrochloride],30-90 min,,IC50,IC50,1.5,uM,DOI:10.1016/S00062952(01)005998   JOURNAL:Biochemical Pharmacology   PAGES:1393   VOLUME:61,Literature,http://dx.doi.org/10.1016/S0006-2952(01)00599-8,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069147,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1.5,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069148,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1.5,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069151,Lapatinib Ditosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1.5,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069154,Lapatinib Ditosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1.5,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070393,Ebastine,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing L5178 cells,,,Rhodamine 123,,,,IC50,IC50,1.5,ŒºM,"Broccatelli, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070394,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,1.5,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070395,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH/3T3 cells,,,Calcein AM,,,,IC50,IC50,1.5,ŒºM,"Pivcevic, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073250,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,1.5,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097872,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,1.5,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069156,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-100 uM,,Quinidine,[Quinidine Sulfate],20-30 min,,IC50,IC50,1.51,uM,DOI:10.1007/s1331811469   JOURNAL:European Journal of Drug Metabolism and Pharmacokinetics   PAGES:115   VOLUME:36,Literature,http://dx.doi.org/10.1007/s13318-011-0046-9,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069159,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.59,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:44 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069160,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.6,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:21 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069161,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.6,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201292/S-000 Part 02, page:30 PDF 9630k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069164,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562/ DOX cells,,,Pirarubicin,[Pirarubicin],,,IC50,IC50,1.6,uM,DOI:10.1016/j.bmcl.2010.11.059   JOURNAL:Bioorganic and Medicinal Chemistry Letters   PAGES:106   VOLUME:21,Literature,http://dx.doi.org/10.1016/j.bmcl.2010.11.059,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069166,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562/ DOX cells,,,Pirarubicin,[Pirarubicin],,,IC50,IC50,1.6,uM,DOI:10.1021/jm8012745   JOURNAL:Journal of Medicinal Chemistry   PAGES:807   VOLUME:52,Literature,http://dx.doi.org/10.1021/jm8012745,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069169,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562/ DOX cells,0-10 uM,,Pirarubicin,[Pirarubicin],,,IC50,IC50,1.6,uM,DOI:10.1021/jm9016174   JOURNAL:Journal of Medicinal Chemistry   PAGES:1755   VOLUME:53,Literature,http://dx.doi.org/10.1021/jm9016174,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070396,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,1.6,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070397,Mibefradil,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.6,ŒºM,"Wandel, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070398,Pentachlorophenol,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,,,Calcein AM,,,,IC50,IC50,1.6,ŒºM,"Georgantzopoulou, 2014",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073252,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50 BA/AB,1.6,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:895   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069172,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,SH-SY-5Y cells,<=10 uM,,Hoechst 33342,[Hoechst 33342],40 min,,IC50,IC50,1.66,uM,DOI:10.1016/j.toxlet.2015.04.005   ISSN:03784274   JOURNAL:Toxicology Letters   PAGES:189   VOLUME:235,Literature,http://dx.doi.org/10.1016/j.toxlet.2015.04.005,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069173,Sirolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.01-10 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,1.67,uM,DOI:10.1038/clpt.2009.266   JOURNAL:Clinical Pharmacology and Therapeutics   PAGES:663   VOLUME:87,Literature,http://dx.doi.org/10.1038/clpt.2009.266,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069174,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-MDR-G185 cells, recombinant",0-100 uM,,Vanadate,[Vanadate],,,IC50,IC50,1.7,uM,DOI:10.1128/AAC.46.1.160165.2002   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:160   VOLUME:46,Literature,http://dx.doi.org/10.1128/AAC.46.1.160-165.2002,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069178,Lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-30 uM,,Rhodamine 123,[Rhodamine],30-60 min,,IC50,IC50,1.7,uM,DOI:10.1097/0000203020030502000023   JOURNAL:AIDS   PAGES:1092   VOLUME:17,Literature,http://dx.doi.org/10.1097/00002030-200305020-00023,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069181,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,1.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069182,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,1.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069187,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[14C]-Ximelagatran,[Ximelagatran],180 min,,IC50,IC50,1.7,uM,DOI:10.1124/dmd.105.008607   JOURNAL:Drug Metabolism and Disposition   PAGES:775   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.008607,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070399,Astemizole,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,1.7,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070400,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,IC50,IC50,1.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070402,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,1.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070403,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,G185 cells,,,Daunorubicin,,,,IC50,IC50,1.7,ŒºM,"Wang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070404,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing Caco2 cells,,,Rhodamine 123,,,,IC50,IC50,1.7,ŒºM,"Vishnuvardhan, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070405,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Hela cells,,,Hoechst 33342,,,,IC50,IC50,1.7,ŒºM,"Cortes-Ciriano, 2013",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070406,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Ximelagatran,,,,IC50,IC50,1.7,ŒºM,"Eriksson, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069188,Istradefylline,CCN1C(=O)N(CC)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(OC)=C3)=N2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.74,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022075/S-000 Part 06, page:31 PDF 4974k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069189,Istradefylline,CCN1C(=O)N(CC)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(OC)=C3)=N2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,1.74,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022075/S-000 Part 06, page:58 PDF 4974k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097613,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDA-MB-435/ LCC6 cells,0.06-10 uM,,Doxorubicin,"[Doxorubicin, Liposomal]",150 min,,Ki,Ki,1.75,uM,DOI:10.1021/jm201121b   JOURNAL:Journal of Medicinal Chemistry   PAGES:1999   VOLUME:55,Literature,http://dx.doi.org/10.1021/jm201121b,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069192,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-100 uM,,Quinidine,[Quinidine Sulfate],20-30 min,,IC50,IC50,1.79,uM,DOI:10.1007/s1331811469   JOURNAL:European Journal of Drug Metabolism and Pharmacokinetics   PAGES:115   VOLUME:36,Literature,http://dx.doi.org/10.1007/s13318-011-0046-9,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069194,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,1.8,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069199,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[14C]-Ximelagatran,[Ximelagatran],180 min,,IC50,IC50,1.8,uM,DOI:10.1124/dmd.105.008607   JOURNAL:Drug Metabolism and Disposition   PAGES:775   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.008607,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069202,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[14C]-Ximelagatran,[Ximelagatran],180 min,,IC50,IC50,1.8,uM,DOI:10.1124/dmd.105.008607   JOURNAL:Drug Metabolism and Disposition   PAGES:775   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.008607,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069204,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[14C]-Ximelagatran,[Ximelagatran],180 min,,IC50,IC50,1.8,uM,DOI:10.1124/dmd.105.008607   JOURNAL:Drug Metabolism and Disposition   PAGES:775   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.008607,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070407,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,1.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070408,Mibefradil,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,1.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070409,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Ximelagatran,,,,IC50,IC50,1.8,ŒºM,"Eriksson, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070410,Telithromycin,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,1.8,ŒºM,"Eberl, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070411,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,1.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097873,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing CEM/VLB100 cells,,,Calcein AM,,,,Ki,Ki,1.8,ŒºM,"Wigler, 1999",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069205,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",12.5-25 uM,,Rivaroxaban,[Rivaroxaban],,,IC50,IC50,1.83,uM,DOI:10.1124/dmd.116.073890   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:260   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073890,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069208,Erlotinib Hydrochloride,Cl.COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],10 min,,IC50,IC50,2,uM,DOI:10.1111/j.13497006.2009.01213.x   JOURNAL:Cancer Science   PAGES:1701   VOLUME:100,Literature,http://dx.doi.org/10.1111/j.1349-7006.2009.01213.x,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069209,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069212,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069213,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069215,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069216,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069218,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070412,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070413,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070414,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073254,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,2,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073257,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,2,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073259,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,2,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073261,Telmisartan,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,2,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097874,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,2,ŒºM,"Cook, 2010",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070302,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",0.01-3000 uM,,Digoxin,[Digoxin],,,IC50,IC50,2.05,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022425/S-000 Part 03, page:7 PDF 4017k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069220,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,2.09,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069223,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,2.1,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069227,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,2.1,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070415,(-)-devapamil,CC(C)[C@](CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,2.1,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070416,Cepharanthin,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,2.1,ŒºM,"Hirai, 1995",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070417,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,IC50,IC50,2.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070418,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2.1,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070419,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Fluo-3,,,,IC50,IC50,2.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070421,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,2.1,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073262,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,2.1,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097875,Trimethoxybenzoylyohimbine,COC1=CC(=CC(=C1OC)OC)C(=O)O[C@H]2CC[C@H]3CN4CCC5=C([C@@H]4C[C@@H]3[C@H]2C(=O)OC)NC6=CC=CC=C56,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing CEM/VLB100 cells,,,"Verapamil2,4",,,,Ki,Ki,2.1,ŒºM,"Shepard, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097876,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing CEM/VLB100 cells,,,"Verapamil2,4",,,,Ki,Ki,2.1,ŒºM,"Shepard, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097877,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,2.18,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069231,Telmisartan,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",,,[3H]-digoxin,[Digoxin],1 h,,IC50,IC50,2.19,uM,DOI:10.1016/j.lfs.2009.11.006   JOURNAL:Life Sciences   PAGES:52   VOLUME:86,Literature,http://dx.doi.org/10.1016/j.lfs.2009.11.006,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069234,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],,,IC50,IC50,2.2,uM,DOI:10.1111/j.13497006.2010.01539.x   JOURNAL:Cancer Science   PAGES:1493   VOLUME:101,Literature,http://dx.doi.org/10.1111/j.1349-7006.2010.01539.x,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070422,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,2.2,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073264,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,2.2,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073266,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,2.2,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073267,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,2.2,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069236,Nilotinib Hydrochloride Monohydrate,O.Cl.CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.5-100 uM,,Afatinib,[Afatinib Dimaleate],,,IC50,IC50,2.22,uM,DOI:10.1016/j.xphs.2019.05.028   ISSN:00223549   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3434   VOLUME:108,Literature,http://dx.doi.org/10.1016/j.xphs.2019.05.028,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069239,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,2.3,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070423,Nelfinavir,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2.3,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070424,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2.3,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097878,Dexniguldipine,CC1=C([C@H](C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing CEM/VLB100 cells,,,Calcein AM,,,,Ki,Ki,2.3,ŒºM,"Wigler, 1999",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097879,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,2.31,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073268,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,2.34,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069243,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HL-60/ VCR cells,,,Daunorubicin,[Daunorubicin Hydrochloride],30-90 min,,IC50,IC50,2.4,uM,DOI:10.1016/S00062952(01)005998   JOURNAL:Biochemical Pharmacology   PAGES:1393   VOLUME:61,Literature,http://dx.doi.org/10.1016/S0006-2952(01)00599-8,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070425,(+)-emopamil,CC(C)[C@@](CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,2.4,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070426,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Fluo-3,,,,IC50,IC50,2.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070427,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,2.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070428,Itraconazole4,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,2.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070429,Verapamil (S),CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCT15/CL02 cells,,,Paclitaxel,,,,IC50,IC50,2.4,ŒºM,"Lee, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069245,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2.5,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070430,Gallopamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,2.5,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070431,Loperamide1,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,2.5,ŒºM,"Wandel, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070432,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2.5,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070433,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,2.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097880,Daunorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,2.5,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070303,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,2.59,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 02, page:28 PDF 752k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070304,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,10 uM,,Digoxin,[Digoxin],,,IC50,IC50,2.59,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 03, page:3 PDF 1205k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070434,(+)-verapamil,CC(C)[C@@](CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,2.6,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070435,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,IC50,IC50,2.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070436,Verapamil (R),CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCT15/CL02 cells,,,Paclitaxel,,,,IC50,IC50,2.6,ŒºM,"Lee, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069250,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2.61,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070437,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,2.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070438,Astemizole,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,2.73,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069252,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,2.78,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070439,Endosulfan,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH/3T3 cells,,,Calcein AM,,,,IC50,IC50,2.8,ŒºM,"Pivcevic, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097616,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,2.81,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097619,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,2.81,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097881,Bromocriptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,2.81,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069256,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,2.86,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069259,Pimozide,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,2.9,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070440,(-)-verapamil,CC(C)[C@](CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,2.9,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070441,Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,2.9,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069260,Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-75 uM,,Digoxin,[Digoxin],2 h,,IC50,IC50,3,uM,DOI:10.1124/dmd.113.051193   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:1575   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.113.051193,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069261,Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-75 uM,,Digoxin 5 uM,[Digoxin],,,IC50,IC50,3,uM,DOI:10.1124/dmd.113.051193   ISSN:1521009X   JOURNAL:Drug Metabolism and Disposition   PAGES:1575   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.113.051193,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069264,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,3,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069266,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,3,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069267,Gefitinib,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.2-400 uM,,[3H]-Mitoxantrone,[Mitoxantrone Hydrochloride],120 min,,IC50,IC50,3,uM,DOI:10.1007/s00280910390   JOURNAL:Cancer Chemotherapy and Pharmacology   PAGES:335   VOLUME:65,Literature,http://dx.doi.org/10.1007/s00280-009-1039-0,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069271,Vismodegib,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],2 h,,IC50,IC50,3,uM,DOI:10.1593/neo.81264   JOURNAL:Neoplasia   PAGES:96   VOLUME:11,Literature,http://dx.doi.org/10.1593/neo.81264,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070443,Phosalone,CCOP(=S)(OCC)SCN1C2=C(C=C(C=C2)Cl)OC1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH/3T3 cells,,,Calcein AM,,,,IC50,IC50,3,ŒºM,"Pivcevic, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073273,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,3,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097882,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,3,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070444,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,3.07,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069275,Tamoxifen Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(C1=CC=CC=C1)=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-30 uM,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,3.2,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069282,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"B16F10 cells, recombinant",,,Doxorubicin,"[Doxorubicin, Liposomal]",4 h,,IC50,IC50,3.2,uM,JOURNAL:Toxicology and Applied Pharmacology   PAGES:288   VOLUME:141,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070445,Gallopamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,IC50,IC50,3.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070446,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,3.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070447,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,3.2,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070448,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,3.2,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070449,Valinomycin,C[C@H]1C(=O)N[C@H](C(=O)O[C@@H](C(=O)N[C@@H](C(=O)O[C@H](C(=O)N[C@H](C(=O)O[C@@H](C(=O)N[C@@H](C(=O)O[C@H](C(=O)N[C@H](C(=O)O[C@@H](C(=O)N[C@@H](C(=O)O1)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,IC50,IC50,3.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070450,Valspodar2,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,,,Calcein AM,,,,IC50,IC50,3.2,ŒºM,"Georgantzopoulou, 2014",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070451,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,3.2,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097883,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,3.23,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069284,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,3.3,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069286,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,3.3,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069288,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,3.4,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070452,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,IC50,IC50,3.4,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070453,Nelfinavir,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,3.4,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097623,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,Ki,Ki,3.4,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:22 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097624,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,Ki,Ki,3.4,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:44 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097625,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,Ki,Ki,3.4,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201292/S-000 Part 02, page:30 PDF 9630k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069292,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,3.5,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069295,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,3.5,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069298,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,3.5,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070454,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,3.5,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070455,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,3.5,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069300,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK (NBL-2) cells, recombinant",0-10 uM,,Calcein AM,[Calcein acetomethoxy ester],30 min,,IC50,IC50,3.6,uM,DOI:10.1016/j.bbrc.2006.05.058   JOURNAL:Biochemical and Biophysical Research Communications   PAGES:45   VOLUME:346,Literature,http://dx.doi.org/10.1016/j.bbrc.2006.05.058,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070456,N-norgallopamil,CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,3.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070457,Propiconazole,CCCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH/3T3 cells,,,Calcein AM,,,,IC50,IC50,3.6,ŒºM,"Pivcevic, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070458,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,3.7,ŒºM,"Kusunoki, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069306,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HL-60/ VCR cells,,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,3.78,uM,DOI:10.1016/S00062952(01)005998   JOURNAL:Biochemical Pharmacology   PAGES:1393   VOLUME:61,Literature,http://dx.doi.org/10.1016/S0006-2952(01)00599-8,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069308,Bepridil Hydrochloride,Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,3.8,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069309,Bepridil Hydrochloride,Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,3.8,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070459,Clarithromycin4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,3.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070460,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,3.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070461,"Ritonavir2,4",CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,3.8,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073275,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,3.8,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073277,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,3.8,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069313,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-25 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,3.89,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069316,Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,3.9,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070462,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,3.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069320,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-100 uM,,Quinidine,[Quinidine Sulfate],20-30 min,,IC50,IC50,3.92,uM,DOI:10.1007/s1331811469   JOURNAL:European Journal of Drug Metabolism and Pharmacokinetics   PAGES:115   VOLUME:36,Literature,http://dx.doi.org/10.1007/s13318-011-0046-9,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097628,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,3.96,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097630,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,3.96,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097632,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,3.96,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097884,Bromocriptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,3.96,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073280,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,4,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073284,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,4,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073285,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,4,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069323,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",,,[3H]-Digoxin,[Digoxin],1 h,,IC50,IC50,4.05,uM,DOI:10.1016/j.lfs.2009.11.006   JOURNAL:Life Sciences   PAGES:52   VOLUME:86,Literature,http://dx.doi.org/10.1016/j.lfs.2009.11.006,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070463,Clarithromycin4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,4.1,ŒºM,"Eberl, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069326,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,4.2,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069329,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,4.2,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069335,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-50 uM,,Daunorubicin,[Daunorubicin Hydrochloride],30 min,,IC50,IC50,4.2,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:1080   VOLUME:29,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070464,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected NIH3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,4.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070465,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,4.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069340,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,4.3,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070466,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,JC-1,,,,IC50,IC50,4.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073288,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,4.3,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073290,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,4.3,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073292,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,4.3,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073294,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,4.3,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069344,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-25 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,4.33,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069348,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,4.39,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069349,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,4.39,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069352,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,4.39,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069353,Daclatasvir Dihydrochloride,Cl.COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,4.4,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206843/S-000, page:319 PDF 31325k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069354,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.3-100 uM,,Digoxin,[Digoxin],90 min,,IC50,IC50,4.4,uM,DOI:10.1016/j.clinthera.2015.09.018   ISSN:01492918   JOURNAL:Clinical Therapeutics   PAGES:2811   VOLUME:37,Literature,http://dx.doi.org/10.1016/j.clinthera.2015.09.018,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069356,Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-75 uM,,Digoxin,[Digoxin],,,IC50,IC50,4.5,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 202324/S-000 Part 03, page:27 PDF 812k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070467,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,4.5,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070468,Sulfentanil,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,4.5,ŒºM,"Wandel, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070470,Manidipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,4.6,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070471,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,4.6,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070472,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,4.6,ŒºM,"Muller, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070473,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,4.6,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073300,Manidipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",5-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],3 h,,IC50,IC50 BA/AB,4.6,uM,JOURNAL:Pharmacological Research   PAGES:1189   VOLUME:17,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097636,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,4.66,uM,DOI:10.1016/S00099236(99)701025   JOURNAL:Clinical Pharmacology and Therapeutics   PAGES:237   VOLUME:65,Literature,http://dx.doi.org/10.1016/S0009-9236(99)70102-5,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097885,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,4.66,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069360,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562/ i-S9 cells,,,Calcein AM,[Calcein acetomethoxy ester],2 h,,IC50,IC50,4.69,uM,DOI:10.1111/j.17470285.2007.00617.x   JOURNAL:Chemical Biology and Drug Design   PAGES:131   VOLUME:71,Literature,http://dx.doi.org/10.1111/j.1747-0285.2007.00617.x,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070474,(-)-isradipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,4.7,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070475,Manidipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,4.7,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070476,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,4.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097886,Nefazodone,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,4.7,ŒºM,"Stormer, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069363,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,4.8,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070477,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,4.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070478,Cyclosporine,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,4.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070479,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,4.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070480,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,4.8,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070481,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,4.8,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070482,Verapamil (Racemic),CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Paclitaxel,,,,IC50,IC50,4.8,ŒºM,"Lee, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069366,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,4.9,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069368,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,4.9,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070483,N-norgallopamil,CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,4.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070484,Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,4.9,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069371,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,5,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069372,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,5,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069373,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,5,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070485,Benidipine,CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,5,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070486,"Ritonavir2,4",CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,5,ŒºM,"Cook, 2010",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073303,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,5,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070487,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,5.2,ŒºM,"Klinkhammer, 2009",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097637,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,5.27,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097642,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,5.27,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097643,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,5.27,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097887,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,5.27,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070488,Haloperidol,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,5.3,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097888,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,Ki,Ki,5.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097889,Verapamil (S),CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Paclitaxel,,,,Ki,Ki,5.3,ŒºM,"Lee, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097645,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",12.5-25 uM,,Rivaroxaban,[Rivaroxaban],,noncompetitive inhibition,Ki,Ki,5.36,uM,DOI:10.1124/dmd.116.073890   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:260   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073890,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069375,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,A2780ADR cells,,,Calcein AM,[Calcein acetomethoxy ester],0-2400 sec,,IC50,IC50,5.4,uM,DOI:10.1016/j.bmc.2010.12.043   JOURNAL:Bioorganic and Medicinal Chemistry   PAGES:2090   VOLUME:19,Literature,http://dx.doi.org/10.1016/j.bmc.2010.12.043,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069379,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,A2780ADR cells,,,[99Tc]-Technetium Tc 99m sestamibi,[Technetium Tc-99m Sestamibi Kit],180 min,,IC50,IC50,5.48,uM,DOI:10.1002/ijc.21827   JOURNAL:International Journal of Cancer   PAGES:414   VOLUME:119,Literature,http://dx.doi.org/10.1002/ijc.21827,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073306,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Digoxin,[Digoxin],3 h,,IC50,IC50 BA/AB,5.48,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073307,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[14C]-Inulin,[Inulin],,,IC50,IC50 BA/AB,5.48,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097890,Amiodarone4,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,Ki,Ki,5.48,ŒºM,"Kakumoto, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097891,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Colchicine,,,,Ki,Ki,5.49,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069381,Trametinib Dimethyl Sulfoxide,CS(C)=O.CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-50 uM,,Digoxin,[Digoxin],,,IC50,IC50,5.5,uM,"FDA approval package document: Pharmacology Review 204114/S-000 Part 08, page:20 PDF 3055k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097892,Verapamil (R),CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Paclitaxel,,,,Ki,Ki,5.5,ŒºM,"Lee, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069382,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-MDR-G185 cells, recombinant",0-180 uM,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,5.6,uM,DOI:10.1128/AAC.46.1.160165.2002   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:160   VOLUME:46,Literature,http://dx.doi.org/10.1128/AAC.46.1.160-165.2002,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069386,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,5.6,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069392,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,5.6,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069395,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,5.6,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069396,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,5.6,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070489,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected NIH3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,5.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070490,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,5.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070491,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,G185 cells,,,Daunorubicin,,,,IC50,IC50,5.6,ŒºM,"Wang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070492,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,5.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070493,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,5.6,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069398,Tafenoquine Succinate,OC(=O)CCC(O)=O.COC1=NC2=C(NC(C)CCCN)C=C(OC)C(OC3=CC(=CC=C3)C(F)(F)F)=C2C(C)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-25 uM,,3H-labeled quinidine,[Quinidine Sulfate],90 min,,IC50,IC50,5.61,uM,"FDA approval package document: Approval Package 210607/S-000 Part 07, page:61 PDF 8273k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069399,Tafenoquine Succinate,OC(=O)CCC(O)=O.COC1=NC2=C(NC(C)CCCN)C=C(OC)C(OC3=CC(=CC=C3)C(F)(F)F)=C2C(C)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-25 uM,,3H-labeled quinidine,[Quinidine Sulfate],90 min,,IC50,IC50,5.61,uM,"FDA approval package document: Approval Package 210607/S-000 Part 07, page:62 PDF 8273k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069400,Tafenoquine Succinate,OC(=O)CCC(O)=O.COC1=NC2=C(NC(C)CCCN)C=C(OC)C(OC3=CC(=CC=C3)C(F)(F)F)=C2C(C)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-25 uM,,3H-labeled quinidine,[Quinidine Sulfate],90 min,,IC50,IC50,5.61,uM,"FDA approval package document: Approval Package 210607/S-000 Part 07, page:63 PDF 8273k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069401,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,5.7,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070494,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,5.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069403,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,A2780ADR cells,0.01-100 uM,,[99Tc]-Technetium Tc 99m sestamibi,[Technetium Tc-99m Sestamibi Kit],60 min,,IC50,IC50,5.74,uM,DOI:10.1007/s0028062443   JOURNAL:Cancer Chemotherapy and Pharmacology   PAGES:61   VOLUME:59,Literature,http://dx.doi.org/10.1007/s00280-006-0244-3,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097648,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,5.78,uM,DOI:10.1016/S00099236(99)701025   JOURNAL:Clinical Pharmacology and Therapeutics   PAGES:237   VOLUME:65,Literature,http://dx.doi.org/10.1016/S0009-9236(99)70102-5,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097649,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,5.78,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097653,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,5.78,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097893,Amiodarone4,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,5.78,ŒºM,"Baltes, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069407,Chlorpromazine Hydrochloride,Cl.CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,5.8,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069416,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,6,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069420,Telmisartan,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,6,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073313,Isradipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,6,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073317,Nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,6,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069421,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,6.1,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070496,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,JC-1,,,,IC50,IC50,6.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097656,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,6.1,uM,DOI:10.1124/jpet.103.055574   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:824   VOLUME:307,Literature,http://dx.doi.org/10.1124/jpet.103.055574,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070497,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Vinblastine1,,,,IC50,IC50,6.18,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069426,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,6.3,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070499,Trifluoperazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,6.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070500,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,6.3,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070501,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Vinblastine1,,,,IC50,IC50,6.34,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070502,Tamoxifen,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,6.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097894,Ergocryptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,6.43,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069428,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,6.5,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070503,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,6.5,ŒºM,"Wandel, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070504,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,6.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070505,Saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,6.5,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070506,Sertindole,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing L5178 cells,,,Rhodamine 123,,,,IC50,IC50,6.5,ŒºM,"Broccatelli, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070507,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,6.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073318,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,6.5,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073320,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,6.5,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073322,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,6.5,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097658,Bromocriptine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=C(Br)NC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N3CCC[C@@]23[H])C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,6.52,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069436,Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,6.6,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070509,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,IC50,IC50,6.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070510,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,6.6,ŒºM,"Muller, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069438,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,6.7,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069443,Spironolactone,[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]33CCC(=O)O3)[C@]1([H])[C@@H](CC1=CC(=O)CC[C@]21C)SC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,6.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069444,Spironolactone,[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]33CCC(=O)O3)[C@]1([H])[C@@H](CC1=CC(=O)CC[C@]21C)SC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,6.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070511,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,6.7,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070512,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,6.7,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070513,Reversan,C1COCCN1CCCNC(=O)C2=C3N=C(C=C(N3N=C2)C4=CC=CC=C4)C5=CC=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,KBV1 cells,,,Calcein AM,,,,IC50,IC50,6.8,ŒºM,"Obreque-Balboa, 2016",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069445,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK-MDR1 cells, recombinant",0.1-1000 uM,,Rivaroxaban,[Rivaroxaban],2 h,,IC50,IC50,6.94,uM,DOI:10.1016/j.ejpb.2020.01.002   ISSN:09396411   JOURNAL:European Journal of Pharmaceutics and Biopharmaceutics   PAGES:27   VOLUME:148,Literature,http://dx.doi.org/10.1016/j.ejpb.2020.01.002,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069452,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,7,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070514,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,7,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069454,Tamoxifen Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(C1=CC=CC=C1)=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,7.1,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070515,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,JC-1,,,,IC50,IC50,7.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070516,Tamoxifen,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected NIH3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,7.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070517,Clarithromycin4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,7.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070518,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,7.2,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070519,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,IC50,IC50,7.2,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070520,Trifluoperazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,7.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070521,Hydramethylnon,CC1(CN=C(NC1)NN=C(/C=C/C2=CC=C(C=C2)C(F)(F)F)/C=C/C3=CC=C(C=C3)C(F)(F)F)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,7.3,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069459,Rolapitant Hydrochloride,Cl.C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,<=20 uM,,Digoxin,[Digoxin],,concentration-dependent inhibition,IC50,IC50,7.36,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206500/S-000, page:43 PDF 6811k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069460,Rolapitant Hydrochloride,Cl.C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],2 h,,IC50,IC50,7.36,uM,"FDA approval package document: Pharmacology Review 206500/S-000, page:62 PDF 27214k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070522,Mibefradil,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,7.4,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070523,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Rhodamine 123,,,,IC50,IC50,7.5,ŒºM,"Stormer, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097661,Sunitinib Malate,O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],,,Ki,Ki,7.6,uM,DOI:10.1111/j.13497006.2010.01539.x   JOURNAL:Cancer Science   PAGES:1493   VOLUME:101,Literature,http://dx.doi.org/10.1111/j.1349-7006.2010.01539.x,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069463,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,7.7,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069465,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,7.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069467,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,7.7,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070325,Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-MDCK cells,10 uM,,Digoxin,[Digoxin],,,IC50,IC50,7.8,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022433/S-000 Part 01, page:4 PDF 1307k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070524,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,7.8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070525,Ophiobolin A,C[C@H]1C[C@@H](O[C@@]12CC[C@]3([C@H]2C/C=C(\[C@@H]4[C@H](C3)[C@](CC4=O)(C)O)/C=O)C)C=C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,7.86,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069471,Montelukast Sodium,[Na+].CC(C)(O)C1=CC=CC=C1CC[C@@H](SCC1(CC1)CC([O-])=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,8,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070526,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070527,Vinblastine,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,8,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097895,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,8.11,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069472,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,8.13,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069474,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,8.13,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069475,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,8.13,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070528,Cholesterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,IC50,IC50,8.2,ŒºM,"Wang, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070529,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Fexofenadine1,3",,,,IC50,IC50,8.44,ŒºM,"Petri, 2004",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069477,Atazanavir Sulfate,OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=NC=CC=C1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ VLB cells,0-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],4 min,,IC50,IC50,8.5,uM,DOI:10.3851/IMP1399   JOURNAL:Antiviral Therapy   PAGES:965   VOLUME:14,Literature,http://dx.doi.org/10.3851/IMP1399,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097896,Doxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,8.5,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097897,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,8.59,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070531,Barnidipine,CC1=C([C@@H](C(=C(N1)C)C(=O)O[C@H]2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,8.6,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070532,N-norgallopamil,CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,8.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073328,Barnidipine,COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC=CC(=C1)N(=O)=O)C(=O)O[C@H]1CCN(C1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",5-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],3 h,,IC50,IC50 BA/AB,8.6,uM,JOURNAL:Pharmacological Research   PAGES:1189   VOLUME:17,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE074699,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Gill cells,1-25 uM,,Calcein,[Calcein acetomethoxy ester],90 min,efflux,IC50,IC50,8.73,uM,DOI:10.1016/j.taap.2016.02.020   ISSN:0041008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:56   VOLUME:297,Literature,http://dx.doi.org/10.1016/j.taap.2016.02.020,2016,IST134,Multidrug resistance protein 1,
ISTE070309,Baloxavir Marboxil,[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@]1([H])C2=C(SCC3=C1C=CC(F)=C3F)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-100 umol/l,,3H-labeled digoxin,[Digoxin],2 h,,IC50,IC50,8.75,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 210854/S-000 Part 02, page:3 PDF 355k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069481,Propranolol Hydrochloride,Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,8.8,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069482,Propranolol Hydrochloride,Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,8.8,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097665,Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,8.8,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097666,Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocytes cells,,,Rhodamine 123,[Rhodamine 123],,,Ki,Ki,8.8,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070533,Simvastatin,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,8.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097668,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",12.5-25 uM,,Rivaroxaban,[Rivaroxaban],,noncompetitive allosteric inhibition,Ki,Ki,8.94,uM,DOI:10.1124/dmd.116.073890   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:260   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073890,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069485,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,Bisbenzimide H33342,[Bisbenzimide H 33342],,,IC50,IC50,9,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069489,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-250 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,9,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070534,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,9,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070535,Simvastatin,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing 3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073333,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,9,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073334,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,9,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069493,Haloperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,9.1,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069495,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",12.5-25 uM,,Rivaroxaban,[Rivaroxaban],,,IC50,IC50,9.2,uM,DOI:10.1124/dmd.116.073890   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:260   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073890,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069496,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,9.2,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069500,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"CR1R12 cells, recombinant",,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,9.2,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070536,(+)-isradipine,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,9.2,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070537,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,9.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070538,Cyclosporine2,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK2 cells,,,Calcein AM,,,,IC50,IC50,9.3,ŒºM,"Tong, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069510,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,9.34,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070539,(-)-nitrendipine,CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,9.4,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070540,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,9.4,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070541,Benidipine,CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,9.5,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070542,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,9.52,ŒºM,"Kakumoto, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073338,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-digoxin,[Digoxin],3 h,,IC50,IC50 BA/AB,9.52,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073339,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[14C]-Inulin,[Inulin],,,IC50,IC50 BA/AB,9.52,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073340,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Digoxin,[Digoxin],3 h,,IC50,IC50 BA/AB,9.52,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073343,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-digoxin,[Digoxin],3 h,,IC50,IC50 BA/AB,9.52,uM,DOI:10.1248/bpb.25.1604   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1604   VOLUME:25,Literature,http://dx.doi.org/10.1248/bpb.25.1604,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070543,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,9.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069514,Budesonide,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.3-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,9.78,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205613/S-000 Part 01, page:28 PDF 5700k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069516,Quetiapine Fumarate,OC(=O)\C=C\C(O)=O.OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,9.8,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069518,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK-MDR1 cells, recombinant",,,Rhodamine 123,[Rhodamine],0-2400 sec,,IC50,IC50,9.8,uM,DOI:10.1016/j.bmc.2010.12.043   JOURNAL:Bioorganic and Medicinal Chemistry   PAGES:2090   VOLUME:19,Literature,http://dx.doi.org/10.1016/j.bmc.2010.12.043,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070544,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Rhodamine 123,,,,IC50,IC50,9.8,ŒºM,"Pick, 2011",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069519,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,10,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069520,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,10,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070545,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,10,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070546,Lovastatin Lactone,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CCC3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Calcein AM,,,,IC50,IC50,10,ŒºM,"Chen, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070547,Mibefradil,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,10,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070548,Moxidectin,[H][C@@]12C\C=C(C)\C[C@@H](C)\C=C\C=C3/CO[C@]4([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O[C@@]([H])(C1)C[C@]1(C\C(=N/OC)[C@H](C)[C@H](O1)C(\C)=C\C(C)C)O2)[C@]34O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Rhodamine 123,,,,IC50,IC50,10,ŒºM,"Griffin, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070549,Quinidine,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,10,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070550,Simvastatin lactone,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Calcein AM,,,,IC50,IC50,10,ŒºM,"Chen, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070551,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,10,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073344,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],,,IC50,IC50 BA/AB,10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073347,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,10,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073349,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,10,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073350,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,10,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073351,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,10,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069525,Lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,10.3,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070552,(+)-nitrendipine,CCOC(=O)C1=C(NC(=C([C@H]1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,F4-6P cells,,,Vinblastine1,,,,IC50,IC50,10.3,ŒºM,"Hollt, 1992",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069528,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HL-60/ VCR cells,,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,10.34,uM,DOI:10.1016/S00062952(01)005998   JOURNAL:Biochemical Pharmacology   PAGES:1393   VOLUME:61,Literature,http://dx.doi.org/10.1016/S0006-2952(01)00599-8,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070553,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,10.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070554,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,IC50,IC50,10.5,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070555,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,10.7,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069536,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"B16F10 cells, recombinant",,,Doxorubicin,"[Doxorubicin, Liposomal]",4 h,,IC50,IC50,10.9,uM,JOURNAL:Toxicology and Applied Pharmacology   PAGES:288   VOLUME:141,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070556,Ivermectin,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,10.9,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070557,Trifluoperazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,10.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069539,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,11,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069540,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,11,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069544,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,11,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069546,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,11,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069547,Benzbromarone,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,11.1,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069552,Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-200 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,11.4,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:1080   VOLUME:29,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070558,Nobiletin,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,IC50,IC50,11.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097898,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,11.5,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069554,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-100 uM,,Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,11.7,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070559,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,IC50,IC50,11.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070560,Desmethylazelastine,C1CC(CCNC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,11.8,ŒºM,"Kakumoto, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070561,Desmethylazelastine,C1CC(CCNC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,11.8,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069561,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,12,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069566,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,12,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070562,"Ritonavir2,4",CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,12,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070563,Saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,12,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070564,Tamoxifen,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,12.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097671,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,12.2,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097673,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,12.2,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097899,Ergocryptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,12.2,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097900,Reserpine2,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,12.2,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073356,Haloperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-20 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,12.43,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069569,Paliperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,12.5,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070566,Barnidipine,CC1=C([C@@H](C(=C(N1)C)C(=O)O[C@H]2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,12.6,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070567,Amiodarone4,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,IC50,IC50,12.8,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069571,Isradipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,13,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069573,Isradipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,13,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069576,Midazolam Hydrochloride,Cl.CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,13,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069578,Midazolam Hydrochloride,Cl.CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,13,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070568,Efonidipine,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,13,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070569,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,13,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070570,Quinidine,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,13,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097901,Ergocristine,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,13.33,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069581,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,13.6,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073361,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,13.6,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069582,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-200 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,13.71,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069584,Diltiazem Hydrochloride,Cl.COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,14,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069585,Diltiazem Hydrochloride,Cl.COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,14,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069588,Diltiazem Malate,O[C@@H](CC(O)=O)C(O)=O.COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,14,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069591,Mifepristone,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@@]1(O)C#CC)C1=CC=C(C=C1)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,14,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070571,Atorvastatin lactone,CC(C)C1=C(C(=C(N1CC[C@@H]2C[C@H](CC(=O)O2)O)C3=CC=C(C=C3)F)C4=CC=CC=C4)C(=O)NC5=CC=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Calcein AM,,,,IC50,IC50,14,ŒºM,"Chen, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070572,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK2 cells,,,Calcein AM,,,,IC50,IC50,14,ŒºM,"Gannon, 2009",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073362,Diltiazem Hydrochloride,Cl.COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,14,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073364,Diltiazem Malate,O[C@@H](CC(O)=O)C(O)=O.COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,14,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097676,Ergotamine Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,14.25,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097680,Ergotamine Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,14.25,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097683,Ergotamine Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,14.25,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097902,Ergotamine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,14.25,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070573,Quinacrine,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,IC50,IC50,14.4,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070574,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Fluo-3,,,,IC50,IC50,14.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069592,Candesartan Cilexetil,CCOC1=NC2=CC=CC(C(=O)OC(C)OC(=O)OC3CCCCC3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",,,[3H]-Digoxin,[Digoxin],1 h,,IC50,IC50,14.7,uM,DOI:10.1016/j.lfs.2009.11.006   JOURNAL:Life Sciences   PAGES:52   VOLUME:86,Literature,http://dx.doi.org/10.1016/j.lfs.2009.11.006,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070575,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,14.9,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097903,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,15,ŒºM,"Horie, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070576,Clarithromycin4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,15.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073371,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,15.1,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097904,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,15.1,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073372,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-50 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,15.37,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070577,Desethylamiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCNCC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,15.4,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070578,Roxithromycin,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,15.4,ŒºM,"Eberl, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073375,Perphenazine,OCCN1CCN(CCCN2C3=CC(Cl)=CC=C3SC3=C2C=CC=C3)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-100 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,15.45,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070579,Piperine,C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,15.5,ŒºM,"Bhardwaj, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070580,"Ritonavir2,4",CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Cyclosporine2,,,,IC50,IC50,15.7,ŒºM,"Kumar, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069601,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,15.8,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069603,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-digoxin,[Digoxin],1-4 h,,IC50,IC50,15.9,uM,DOI:10.1177/0091270010376193   JOURNAL:Journal of Clinical Psychopharmacology   PAGES:761   VOLUME:51,Literature,http://dx.doi.org/10.1177/0091270010376193,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070311,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.1-50 uM,,Digoxin,[Digoxin],,,IC50,IC50,15.9,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022275/S-000 Part 02, page:8 PDF 10667k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069616,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,16,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070582,Azelastine,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,16,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070583,Loperamide1,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,16,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073380,Azelastine Hydrochloride,Cl.CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],0-3 h,,IC50,IC50 BA/AB,16,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073381,Azelastine Hydrochloride,Cl.CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[14C]-Inulin,[Inulin],,,IC50,IC50 BA/AB,16,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097905,Dihydroergocristine,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,16,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069619,Sunitinib Malate,O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,[3H]-Vincristine,[Vincristine Sulfate],,,IC50,IC50,16.2,uM,DOI:10.1111/j.13497006.2010.01539.x   JOURNAL:Cancer Science   PAGES:1493   VOLUME:101,Literature,http://dx.doi.org/10.1111/j.1349-7006.2010.01539.x,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE098404,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,50 uM,,[3H]-Vinblastine sulfate,[Vinblastine Sulfate],0-30 min,,Ki,Ki BA/AB,16.2,uM,JOURNAL:Journal of Biological Chemistry   PAGES:14991   VOLUME:268,Literature,,1993,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069620,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"B16F10 cells, recombinant",,,Doxorubicin,"[Doxorubicin, Liposomal]",4 h,,IC50,IC50,16.6,uM,JOURNAL:Toxicology and Applied Pharmacology   PAGES:288   VOLUME:141,Literature,,1996,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070584,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,16.6,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097686,Glasdegib,OC(=O)\C=C/C(O)=O.CN1CC[C@H](C[C@@H]1C1=NC2=C(N1)C=CC=C2)NC(=O)NC1=CC=C(C=C1)C#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,Digoxin,[Digoxin],,,Ki,Ki,16.7,uM,"EMA approval document: Public Assessment Report EMA/CHMP/284008/2020; EMEA/H/C/004878/0000, page:66 PDF 4698k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069624,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,17,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069629,Repaglinide,CCOC1=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,17,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE098407,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1 mM,,[3H]-Vinblastine sulfate,[Vinblastine Sulfate],0-30 min,,Ki,Ki BA/AB,17.05,uM,JOURNAL:Journal of Biological Chemistry   PAGES:14991   VOLUME:268,Literature,,1993,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070585,Efonidipine,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,17.3,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070586,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Colchicine,,,,IC50,IC50,17.3,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070587,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,IC50,IC50,17.5,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073382,Nicardipine Hydrochloride,Cl.COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",5-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],3 h,,IC50,IC50 BA/AB,17.5,uM,JOURNAL:Pharmacological Research   PAGES:1189   VOLUME:17,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070588,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,17.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073386,Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-250 uM,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,17.7,uM,DOI:10.1007/s0021014897   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:551   VOLUME:364,Literature,http://dx.doi.org/10.1007/s00210-001-0489-7,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070589,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,"Digoxin1,3",,,,IC50,IC50,17.8,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070590,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,17.9,ŒºM,"Pauli-Magnus, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073387,Pantoprazole Sodium,[Na+].COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-250 uM,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,17.9,uM,DOI:10.1007/s0021014897   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:551   VOLUME:364,Literature,http://dx.doi.org/10.1007/s00210-001-0489-7,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069636,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,18,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070591,Nilvadipine,CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,18,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070592,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected NIH3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,18,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073389,Ranolazine,COC1=CC=CC=C1OCC(O)CN1CCN(CC1)CC(=O)NC1=C(C)C=CC=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,18,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073392,Troglitazone,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,18,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097689,Imatinib Mesylate,CS(O)(=O)=O.CN1CCN(CC1)CC1=CC=C(C=C1)C(=O)NC1=CC(NC2=NC(=CC=N2)C2=CN=CC=C2)=C(C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,18.3,uM,DOI:10.1124/jpet.103.055574   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:824   VOLUME:307,Literature,http://dx.doi.org/10.1124/jpet.103.055574,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073393,Flupentixol,OCCN1CCN(CC\C=C2/C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-100 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,18.32,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069642,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-MDR1 cells, recombinant",1-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,18.7,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:212 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070593,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,18.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069644,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,18.9,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069645,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK (NBL-2) cells,,,Digoxin,[Digoxin],,,IC50,IC50,19,uM,"EMA approval document: Assessment Report EMA/374133/2013; EMEA/H/C/002649/0000, page:35 PDF 1815k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069646,Troglitazone,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,19,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073397,Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,19,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069649,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,19.04,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069651,Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,19.2,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097906,Dihydroergocryptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,19.82,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069654,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,19.9,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070594,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,19.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069658,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,20,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069659,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.2-400 uM,,[3H]-Vinblastine,[Vinblastine Sulfate],120 min,,IC50,IC50,20,uM,DOI:10.1021/jm060639z   JOURNAL:Journal of Medicinal Chemistry   PAGES:6607   VOLUME:49,Literature,http://dx.doi.org/10.1021/jm060639z,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069664,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,20,uM,DOI:10.1124/dmd.105.007377   JOURNAL:Drug Metabolism and Disposition   PAGES:203   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.007377,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069667,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,20,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073404,Ruxolitinib Phosphate,OP(O)(O)=O.N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50 BA/AB,21,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 202192/S-000 Part 05, page:2 PDF 295k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069668,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-1000 uM,,Rivaroxaban,[Rivaroxaban],2 h,,IC50,IC50,21.2,uM,DOI:10.1016/j.ejpb.2020.01.002   ISSN:09396411   JOURNAL:European Journal of Pharmaceutics and Biopharmaceutics   PAGES:27   VOLUME:148,Literature,http://dx.doi.org/10.1016/j.ejpb.2020.01.002,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069669,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-50 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,21.38,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070596,Tebufenozide,CCC1=CC=C(C=C1)C(=O)NN(C(=O)C2=CC(=CC(=C2)C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Quinidine1,2,4",,,,IC50,IC50,21.5,ŒºM,"Miyata, 2016",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070597,Azithromycin,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,21.8,ŒºM,"Eberl, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069673,Conivaptan Hydrochloride,Cl.CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,22,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073407,Amlodipine Besylate,OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",5-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],3 h,,IC50,IC50 BA/AB,22,uM,JOURNAL:Pharmacological Research   PAGES:1189   VOLUME:17,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073408,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,22,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097907,Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Daunorubicin,,,,Ki,Ki,22,ŒºM,"Katoh, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097908,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,22.4,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073410,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Daunorubicin,[Daunorubicin Hydrochloride],0-3 h,,IC50,IC50 BA/AB,22.5,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073412,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[14C]-Inulin,[Inulin],,,IC50,IC50 BA/AB,22.5,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097909,Amiodarone4,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,Daunorubicin,,,,Ki,Ki,22.5,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097910,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,Ki,Ki,22.5,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097911,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,Ki,Ki,22.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097912,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,Ki,Ki,22.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097913,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,Ki,Ki,22.7,ŒºM,"Eberl, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097914,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Vinblastine1,,,,Ki,Ki,22.9,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069678,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,23,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069679,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,23,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069680,Sertraline Hydrochloride,Cl.CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,23,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069682,Sertraline Hydrochloride,Cl.CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,23,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097915,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,23,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097916,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,Ki,Ki,23.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097917,Spironolactone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-G185 cells,,,Daunorubicin,,,,Ki,Ki,23.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070598,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,23.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097918,Clarithromycin4,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,Ki,Ki,23.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069684,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,24,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:21 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069685,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,24,uM,"EMA approval document: Assessment Report EMA/491185/2013; EMEA/H/C/002280, page:44 PDF 5069k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069686,Afatinib Dimaleate,OC(=O)\C=C/C(O)=O.CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,24,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201292/S-000 Part 02, page:30 PDF 9630k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069687,Chlorpromazine Hydrochloride,Cl.CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,24,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069689,Chlorpromazine Hydrochloride,Cl.CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,24,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069691,Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Hamster cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,24,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021445/S-000 Part 01, page:18 PDF 1823k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069694,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,24.2,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070312,Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-100 uM,,Taxol,[Paclitaxel],120 min,,IC50,IC50,24.2,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022187/S-000 Part 05, page:65 PDF 6543k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097919,Ergocornine,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,24.5,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097691,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,24.6,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097692,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocytes cells,,,Rhodamine 123,[Rhodamine 123],,,Ki,Ki,24.6,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097693,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,24.6,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097694,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,24.6,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097695,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,24.9,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097698,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,24.9,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097920,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,24.9,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069702,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.02-60 ug/mL,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,IC50,IC50,25,uM,DOI:10.1124/jpet.110.175034   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:223   VOLUME:336,Literature,http://dx.doi.org/10.1124/jpet.110.175034,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069703,Sorafenib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.02-60 ug/mL,,[3H]-vinblastine,[Vinblastine Sulfate],,,IC50,IC50,25,uM,DOI:10.1124/jpet.110.175034   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:223   VOLUME:336,Literature,http://dx.doi.org/10.1124/jpet.110.175034,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073415,Conivaptan Hydrochloride,Cl.CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,25,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097921,Desethylamiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCNCC)I,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,Ki,Ki,25.2,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069706,Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,25.3,uM,"FDA approval package document: Pharmacology Review 021445/S-000 Part 02, page:16 PDF 1465k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069707,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388/ DX cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,25.7,uM,DOI:10.1016/j.ejphar.2011.04.003   JOURNAL:European Journal of Pharmacology   PAGES:298   VOLUME:660,Literature,http://dx.doi.org/10.1016/j.ejphar.2011.04.003,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097922,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,25.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069710,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-250 uM,,Daunorubicin,[Daunorubicin Hydrochloride],30 min,,IC50,IC50,26,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069715,Memantine Hydrochloride,Cl.[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,26,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069718,Memantine Hydrochloride,Cl.[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,26,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097923,Lovastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing 3T3-G185 cells,,,Daunorubicin,,,,Ki,Ki,26,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097924,Simvastatin,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,Ki,Ki,26.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097925,Felodipine,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,Ki,Ki,26.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097702,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,26.36,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097704,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,26.36,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097708,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,26.36,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097926,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,26.36,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097927,Cnidiadin,CC(C)C(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,,,Vinblastine1,,,,Ki,Ki,26.4,ŒºM,"Barthomeuf, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097928,Coumaphos,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,Ki,Ki,26.9,ŒºM,"Bain, 1997",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069719,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"K562 cells, recombinant",,,Calcein acetoxymethylester,[Calcein acetomethoxy ester],15 min,,IC50,IC50,26.96,uM,DOI:10.1016/j.ejps.2013.04.032   ISSN:09280987   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:773   VOLUME:49,Literature,http://dx.doi.org/10.1016/j.ejps.2013.04.032,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069723,Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-100 uM,,[3H]-digoxin,[Digoxin],120 min,,IC50,IC50,27,uM,DOI:10.1002/bdd.1801   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:304   VOLUME:33,Literature,http://dx.doi.org/10.1002/bdd.1801,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069725,Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-200 uM,,Daunorubicin,[Daunorubicin Hydrochloride],,,IC50,IC50,27.8,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073417,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Rivaroxaban,[Rivaroxaban],0-2 h,,IC50,IC50 BA/AB,27.9,uM,DOI:10.1124/jpet.111.180240   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:372   VOLUME:338,Literature,http://dx.doi.org/10.1124/jpet.111.180240,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097929,"Ritonavir2,4",CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII-MDR1 cells,,,"Digoxin1,3",,,,Ki,Ki,28.2,ŒºM,"Keogh, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097711,Nelfinavir Mesylate,CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=CC=CC(O)=C1C)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,28.6,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069734,Atazanavir Sulfate,OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=NC=CC=C1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-50 uM,,[3H]-Digoxin,[Digoxin],,,IC50,IC50,28.7,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021567/S-000 Part 04, page:35 PDF 1402k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069736,Prazosin Hydrochloride,Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,28.7,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097930,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,Ki,Ki,28.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097931,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Irinotecan,,,,Ki,Ki,29,ŒºM,"Luo, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097932,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing MDCK cells,,,Calcein AM,,,,Ki,Ki,29,ŒºM,"Chen, 2005",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097933,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,29.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069742,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,29.8,uM,DOI:10.1124/dmd.105.007377   JOURNAL:Drug Metabolism and Disposition   PAGES:203   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.007377,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069743,Paroxetine Mesylate,CS(O)(=O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,29.8,uM,DOI:10.1124/dmd.105.007377   JOURNAL:Drug Metabolism and Disposition   PAGES:203   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.007377,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097713,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,29.92,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097715,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,29.92,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097719,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,29.92,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097934,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,29.92,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE055742,Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CR1R12 cells,,,Ketoconazole,[Ketoconazole],,,IC50,IC50,30,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021445/S-000 Part 01, page:18 PDF 1823k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069746,Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-100 uM,,Rhodamine 123,[Rhodamine 123],1 h,,IC50,IC50,30,uM,DOI:10.1007/s0021364379   JOURNAL:Psychopharmacology   PAGES:415   VOLUME:187,Literature,http://dx.doi.org/10.1007/s00213-006-0437-9,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069748,Diltiazem Hydrochloride,Cl.COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,30,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069751,Diltiazem Malate,O[C@@H](CC(O)=O)C(O)=O.COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,30,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069753,Prazosin Hydrochloride,Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,30,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069754,Prazosin Hydrochloride,Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,30,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069757,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,30,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073424,Azelastine Hydrochloride,Cl.CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Digoxin,[Digoxin],0-3 h,,IC50,IC50 BA/AB,30,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097935,Azelastine,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,Ki,Ki,30,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097936,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Colchicine,,,,Ki,Ki,30.1,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069761,Atazanavir Sulfate,OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=NC=CC=C1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-75 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,30.44,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097937,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,Ki,Ki,30.5,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069763,Isradipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,31,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097938,Tamoxifen,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,31.4,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097939,Felodipine,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,Ki,Ki,32.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097940,Lovastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,Ki,Ki,32.7,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097941,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,33,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069767,Glasdegib,OC(=O)\C=C/C(O)=O.CN1CC[C@H](C[C@@H]1C1=NC2=C(N1)C=CC=C2)NC(=O)NC1=CC=C(C=C1)C#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,,,Digoxin,[Digoxin],,,IC50,IC50,33.3,uM,"EMA approval document: Public Assessment Report EMA/CHMP/284008/2020; EMEA/H/C/004878/0000, page:66 PDF 4698k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097942,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK II-MDR1 cells,,,Vinblastine1,,,,Ki,Ki,33.5,ŒºM,"Rautio, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069769,Atazanavir Sulfate,OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=NC=CC=C1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-75 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,33.78,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073427,Fluphenazine Decanoate,CCCCCCCCCC(=O)OCCN1CCN(CCCN2C3=CC(=CC=C3SC3=C2C=CC=C3)C(F)(F)F)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-100 uM,,[3H]-Talinolol,[Talinolol],,,IC50,IC50 BA/AB,33.88,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073429,Fluphenazine Hydrochloride,Cl.OCCN1CCN(CCCN2C3=CC(=CC=C3SC3=C2C=CC=C3)C(F)(F)F)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-100 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,33.88,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097943,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,33.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069772,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,34,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069774,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,34,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069777,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",,,[3H]-digoxin,[Digoxin],1 h,,IC50,IC50,34,uM,DOI:10.1016/j.lfs.2009.11.006   JOURNAL:Life Sciences   PAGES:52   VOLUME:86,Literature,http://dx.doi.org/10.1016/j.lfs.2009.11.006,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069780,Ranolazine,COC1=CC=CC=C1OCC(O)CN1CCN(CC1)CC(=O)NC1=C(C)C=CC=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,34,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069783,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,34,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069785,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,34,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073430,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,34,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097944,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,Ki,Ki,34,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097945,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CEM cells,,,Calcein AM,,,,Ki,Ki,34,ŒºM,"Tiberghien, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069786,Lefamulin Acetate,CC(O)=O.[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,34.1,uM,"FDA approval package document: Approval Package 211672/S-000 Part 07, page:8 PDF 839k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097946,Endosulfan,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,Ki,Ki,34.1,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097947,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,Ki,Ki,34.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069787,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-75 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,34.77,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069789,Nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,35,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069790,Nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,35,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097948,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,Ki,Ki,35.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069795,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,36,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097949,Ketoconazole2,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,Ki,Ki,36,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097950,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,36.5,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097722,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,37.79,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097725,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,37.79,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097726,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,37.79,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097951,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,37.79,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097952,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,Ki,Ki,38.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069797,Sunitinib Malate,O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCT-8 cells,,,Rhodamine 123,[Rhodamine],,,IC50,IC50,39,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021938/S-000; 021968/S-000, page:51 PDF 7439k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069806,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,39.6,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069809,Amprenavir,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,40,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097953,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,Ki,Ki,40,ŒºM,"Kakumoto, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097728,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,40.1,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097730,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocytes cells,,,Rhodamine 123,[Rhodamine 123],,,Ki,Ki,40.1,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069810,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-75 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,40.48,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069814,Nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,41,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097954,Desmethylazelastine,C1CC(CCNC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 transfected LLC-PK1 cells,,,"Digoxin1,3",,,,Ki,Ki,41.8,ŒºM,"Katoh, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069815,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MCF-7/ Dox cells, recombinant",,,Rhodamine 123,[Rhodamine 123],30 min,,IC50,IC50,42,uM,DOI:10.1124/mol.108.050492   JOURNAL:Molecular Pharmacology   PAGES:92   VOLUME:75,Literature,http://dx.doi.org/10.1124/mol.108.050492,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069817,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MCF-7/ Dox cells, recombinant",,,Rhodamine 123,[Rhodamine 123],30 min,,IC50,IC50,42,uM,DOI:10.1124/mol.108.050492   JOURNAL:Molecular Pharmacology   PAGES:92   VOLUME:75,Literature,http://dx.doi.org/10.1124/mol.108.050492,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069818,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MCF-7/ Dox cells, recombinant",,,Rhodamine 123,[Rhodamine 123],30 min,,IC50,IC50,42,uM,DOI:10.1124/mol.108.050492   JOURNAL:Molecular Pharmacology   PAGES:92   VOLUME:75,Literature,http://dx.doi.org/10.1124/mol.108.050492,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097955,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,JC-1,,,,Ki,Ki,42,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069819,Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Rhodamine 123,[Rhodamine],,,IC50,IC50,42.3,uM,"FDA approval package document: Pharmacology Review 021445/S-000 Part 02, page:16 PDF 1465k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097956,Diltiazem,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Calcein AM,,,,Ki,Ki,42.7,ŒºM,"Muller, 2007",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097957,Diltiazem,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing A2780/ADR cells,,,Hoechst 33342,,,,Ki,Ki,42.7,ŒºM,"Pick, 2008",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097958,Ergocristine,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,42.8,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069821,Desloratadine,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-200 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,43,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:1080   VOLUME:29,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070599,Indinavir,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Digoxin1,3",,,,IC50,IC50,44,ŒºM,"Choo, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073438,Indinavir Sulfate,OS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2)CC1=CC=CN=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,44,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073439,Indinavir Sulfate,OS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2)CC1=CC=CN=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,44,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073442,Indinavir Sulfate,OS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2)CC1=CC=CN=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,44,uM,JOURNAL:Drug Metabolism and Disposition   PAGES:655   VOLUME:28,Literature,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097732,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,44,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097735,Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,44,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097959,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,44,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070600,Nisoldipine,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,44.1,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073445,Amiodarone Hydrochloride,Cl.CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-GA5-COL150 cells, recombinant",0-50 uM,,[3H]-Digoxin,[Digoxin],0-3 h,,IC50,IC50 BA/AB,45.6,uM,DOI:10.1016/S09280987(00)002153   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:505   VOLUME:12,Literature,http://dx.doi.org/10.1016/S0928-0987(00)00215-3,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073447,Domperidone,ClC1=CC=C2N(C3CCN(CCCN4C(=O)NC5=CC=CC=C45)CC3)C(=O)NC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-150 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,45.64,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069831,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,46,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069834,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-250 uM,,Rhodamine 123,[Rhodamine],30 min,,IC50,IC50,46,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069838,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,47,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069840,Flecainide Acetate,CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC1CCCCN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,48,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069841,Flecainide Acetate,CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC1CCCCN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,48,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069844,Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-MDR-G185 cells, recombinant",0-250 uM,,Rhodamine 123,[Rhodamine],,,IC50,IC50,48.8,uM,DOI:10.1128/AAC.46.1.160165.2002   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:160   VOLUME:46,Literature,http://dx.doi.org/10.1128/AAC.46.1.160-165.2002,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069849,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-500 uM,,[Bodipy]-Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,51.9,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069851,Edoxaban Tosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]1C[C@H](CC[C@@H]1NC(=O)C(=O)NC1=NC=C(Cl)C=C1)C(=O)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1 uM,,Edoxaban,[Digoxin],,,IC50,IC50,53.7,uM,DOI:10.1124/dmd.113.054866   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:520   VOLUME:42,Literature,http://dx.doi.org/10.1124/dmd.113.054866,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069852,Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,54,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069855,Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",,,Verapamil,[Verapamil Hydrochloride],,,IC50,IC50,54,uM,JOURNAL:Cancer Research   PAGES:7525   VOLUME:61,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097738,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,55.5,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097741,Miconazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,55.5,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097960,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,55.5,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069863,Testosterone,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H],MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,56.4,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069867,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,57,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069871,Citalopram Hydrobromide,Br.CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,58,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069872,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-500 uM,,[Bodipyl-FL]-Prazosin,[Prazosin Hydrochloride],,,IC50,IC50,58.55,uM,DOI:10.1002/jps.22566   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:3055   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22566,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069875,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"CR1R12 cells, recombinant",0-250 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,59,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069881,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,61,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069882,Paroxetine Mesylate,CS(O)(=O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,61,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073455,Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-250 uM,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,62.8,uM,DOI:10.1007/s0021014897   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:551   VOLUME:364,Literature,http://dx.doi.org/10.1007/s00210-001-0489-7,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069886,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,63,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069887,Methylene Blue,[Cl-].CN(C)C1=CC2=C(C=C1)N=C1C=C/C(/C=C1S2)=[N+](\C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,64.6,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204630/S-000, page:20 PDF 8111k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073457,Losartan Potassium,[K+].CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,65,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069891,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-250 uM,,Rhodamine 123,[Rhodamine],30 min,,IC50,IC50,67,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069893,Atazanavir Sulfate,OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=NC=CC=C1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,67.8,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069898,Pantoprazole Sodium,[Na+].COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,69,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069900,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-MDR1 cells, recombinant",1-300 uM,,Digoxin,[Digoxin],,,IC50,IC50,73,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:212 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069901,Midazolam Hydrochloride,Cl.CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,73.9,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069904,Fluvastatin Sodium,[Na+].CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,5-Thio-tetramethylrosamine,[Thio-tetramethylrosamine],,,IC50,IC50,75,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069910,Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,80.5,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097746,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocyte cells,,,Rhodamine 123,[Rhodamine 123],30 min,,Ki,Ki,82.4,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097747,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Lymphocytes cells,,,Rhodamine 123,[Rhodamine 123],,,Ki,Ki,82.4,uM,JOURNAL:Pharmacological Research   PAGES:39   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069911,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,83,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069921,Paliperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-100 uM,,[3H]-digoxin,[Digoxin],120 min,,IC50,IC50,85,uM,DOI:10.1002/bdd.1801   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:304   VOLUME:33,Literature,http://dx.doi.org/10.1002/bdd.1801,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069922,Simeprevir Sodium,[Na+].[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-100 uM,,Taxol,[Paclitaxel],,,IC50,IC50,85.9,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205123/S-000 Part 06, page:18 PDF 4160k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069923,Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,86.9,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097748,Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,87.64,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097752,Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,87.64,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097755,Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,87.64,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097961,Troleandomycin,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,87.64,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073462,Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-250 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,92.78,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097756,Ergotamine Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,98.9,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097759,Ergotamine Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,98.9,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097962,Ergotamine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,98.9,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069933,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,HCMEC/ D3 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,100,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069936,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,100,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069940,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,100,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073465,Caffeine Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1C=NC2=C1C(=O)N(C)C(=O)N2C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073467,Chlorzoxazone,ClC1=CC2=C(OC(=O)N2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073470,Fexofenadine Hydrochloride,Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073471,Morphine Sulfate,O.OS(O)(=O)=O.[H][C@@]12C=C[C@H](O)[C@@H]3OC4=C(O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073473,Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],4 h,,IC50,IC50 BA/AB,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097764,Ergonovine Maleate,OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CNC4=CC=CC(C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO)=C34,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097766,Ergonovine Maleate,OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CNC4=CC=CC(C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO)=C34,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097767,Ergonovine Maleate,OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CNC4=CC=CC(C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO)=C34,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097963,Ergonovine,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,100,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069942,Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"HEK 293 Flp-In cells, recombinant",,,Rhodamine 123,[Rhodamine 123],5 min,,IC50,IC50,100.41,uM,DOI:10.1097/FPC.0b013e3282f85e36   JOURNAL:Pharmacogenetics and Genomics   PAGES:390   VOLUME:18,Literature,http://dx.doi.org/10.1097/FPC.0b013e3282f85e36,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069944,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"CR1R12 cells, recombinant",0-250 uM,,Daunorubicin,[Daunorubicin Hydrochloride],30 min,,IC50,IC50,102,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069950,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MCF-7/ Dox cells, recombinant",,,Rhodamine 123,[Rhodamine 123],30 min,,IC50,IC50,103,uM,DOI:10.1124/mol.108.050492   JOURNAL:Molecular Pharmacology   PAGES:92   VOLUME:75,Literature,http://dx.doi.org/10.1124/mol.108.050492,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097964,Ergocornine,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,105.2,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069951,Pantoprazole Sodium,[Na+].COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,108,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097773,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,111,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097965,Daunorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing MDCK cells,,,"Digoxin1,3",,,,Ki,Ki,111,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069956,Fluoxetine Hydrochloride,Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,115.5,uM,DOI:10.1124/dmd.105.007377   JOURNAL:Drug Metabolism and Disposition   PAGES:203   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.007377,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097776,Ergonovine Maleate,OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CNC4=CC=CC(C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO)=C34,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,115.5,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097779,Ergonovine Maleate,OC(=O)\C=C/C(O)=O.[H][C@@]12CC3=CNC4=CC=CC(C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO)=C34,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,115.5,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097966,Ergonovine,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,115.5,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069959,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[14C]-Ximelagatran,[Ximelagatran],180 min,,IC50,IC50,119,uM,DOI:10.1124/dmd.105.008607   JOURNAL:Drug Metabolism and Disposition   PAGES:775   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.105.008607,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097782,Dihydroergotamine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,119.94,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097784,Dihydroergotamine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,119.94,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097785,Dihydroergotamine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,119.94,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097967,Dihydroergotamine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,119.94,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069962,Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",1-1000 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,123,uM,DOI:10.1038/clpt.2011.255   JOURNAL:Clinical Pharmacology and Therapeutics   PAGES:506   VOLUME:91,Literature,http://dx.doi.org/10.1038/clpt.2011.255,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069966,Gemifloxacin Mesylate,CS(O)(=O)=O.CO\N=C1/CN(CC1CN)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",1-1000 uM,,[14C]-Erythromycin,[Erythromycin],30 min,,IC50,IC50,123,uM,DOI:10.1016/j.ijpharm.2011.08.009   JOURNAL:International Journal of Pharmacology   PAGES:26   VOLUME:420,Literature,http://dx.doi.org/10.1016/j.ijpharm.2011.08.009,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073475,Amisulpride,CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-250 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,123.5,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070601,Azinphos-ethyl,CCOP(=S)(OCC)SCN1C(=O)C2=CC=CC=C2N=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,129,ŒºM,"Bain, 1997",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069970,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,130,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070602,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Fluo-3,,,,IC50,IC50,130.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069971,Eravacycline dihydrochloride,Cl.[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Digoxin,[Digoxin],,estimated; for hepatic efflux,IC50,IC50,135,uM,"FDA approval package document: Approval Package 211109/S-000 Part 10, page:38 PDF 8064k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069972,Eravacycline dihydrochloride,Cl.[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Digoxin,[Digoxin],,estimated; for renal efflux,IC50,IC50,135,uM,"FDA approval package document: Approval Package 211109/S-000 Part 10, page:38 PDF 8064k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069973,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK-BCRP cells, recombinant",0.1-1000 uM,,Rivaroxaban,[Rivaroxaban],2 h,,IC50,IC50,137.8,uM,DOI:10.1016/j.ejpb.2020.01.002   ISSN:09396411   JOURNAL:European Journal of Pharmaceutics and Biopharmaceutics   PAGES:27   VOLUME:148,Literature,http://dx.doi.org/10.1016/j.ejpb.2020.01.002,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097968,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing MDCK cells,,,"Digoxin1,3",,,,Ki,Ki,140,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070603,Chlorpyrifos,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,140.6,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073481,Fluvoxamine Maleate,OC(=O)\C=C/C(O)=O.COCCCC\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-250 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,146.7,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097855,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.01-0.30 umol/L,,Loperamide Hydrochloride,[Loperamide Hydrochloride],2 h,,Ki,Ki,148,umol/L,DOI:10.1124/dmd.112.049577   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:683   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.049577,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069975,Propranolol Hydrochloride,Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,150,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069978,Fluvastatin Sodium,[Na+].CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,151,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070604,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,157,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070605,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,JC-1,,,,IC50,IC50,159.3,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070606,(+)-citronellal,C[C@H](CCC=C(C)C)CC=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,167,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070607,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Calcein AM,,,,IC50,IC50,167.8,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073483,Rifampin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(C)CC1)=C2O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.1-100 uM,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,169,uM,DOI:10.1038/clpt.2010.271   JOURNAL:Clinical Pharmacology and Therapeutics   PAGES:234   VOLUME:89,Literature,http://dx.doi.org/10.1038/clpt.2010.271,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070608,Abietic acid,CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,172,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069983,Imipramine Hydrochloride,Cl.CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,180,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069986,Imipramine Pamoate,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12.OC(=O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C2C=CC=CC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,180,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069989,Alprenolol,CC(C)NCC(O)COC1=CC=CC=C1CC=C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,181,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070609,Cucurbitacin I,C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C=C(C(=O)C4(C)C)O)C)C)[C@](C)(C(=O)/C=C/C(C)(C)O)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,181,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069990,Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Hamster cells, recombinant",,,Rhodamine,[Rhodamine],,,IC50,IC50,184,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021445/S-000 Part 01, page:18 PDF 1823k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070610,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,IC50,IC50,184.9,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070611,Forskolin,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,188.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069991,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,189,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070612,Dicapthon,COP(=S)(OC)OC1=C(C=C(C=C1)[N+](=O)[O-])Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,191.7,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070613,Progesterone,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,192.2,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070614,Chloropromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,196,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097789,Ranolazine,COC1=CC=CC=C1OCC(O)CN1CCN(CC1)CC(=O)NC1=C(C)C=CC=C1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCK-MDR1 cells, recombinant",,,Digoxin,[Digoxin],,,Ki,Ki,197,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021526/S-000 Part 02, page:43 PDF 4215k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069994,Fluvastatin Sodium,[Na+].CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,Bisbenzimide H33342,[Bisbenzimide H 33342],,,IC50,IC50,200,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069996,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,200,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069998,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,200,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE069999,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,200,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070615,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Tetramethylrosamine,,,,IC50,IC50,207.1,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070000,Roxithromycin,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,213,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097969,Vincristine,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing MDCK cells,,,"Digoxin1,3",,,,Ki,Ki,213,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070006,Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,214,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070010,Desipramine Hydrochloride,Cl.CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,221,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070616,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,224,ŒºM,"Kawahara, 2000",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070617,Parathion,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,B16/F10 cells,,,Doxorubicin,,,,IC50,IC50,229.8,ŒºM,"Bain, 1996",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070618,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,237,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070015,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-500 uM,,Vanadate,[Vanadate],30 min,,IC50,IC50,271,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070619,Atorvastatin,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing 3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,271,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097970,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,276,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070018,Rosuvastatin Calcium,[Ca++].CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,Bisbenzimide H33342,[Bisbenzimide H 33342],,,IC50,IC50,280,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070620,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,280,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070020,Sitagliptin Phosphate,O.OP(O)(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,300,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070023,Sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C2=C(C(=O)C(=CN2C2CC2)C(O)=O)C(N)=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,300,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070030,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"NIH-3T3 cells, recombinant",0-500 uM,,Rhodamine 123,[Rhodamine],30 min,,IC50,IC50,307,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070621,Atorvastatin,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing 3T3-G185 cells,,,Rhodamine 123,,,,IC50,IC50,307,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070031,Tofacitinib Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,,IC50,IC50,311,uM,"EMA approval document: Assessment Report EMA/CHMP/425279/2013; EMEA/H/C/002542/0000, page:38 PDF 4773k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070313,Tofacitinib Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,<=1000 uM,,Digoxin,[Digoxin],,,IC50,IC50,311,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 203214/S-000 Part 03, page:6 PDF 4276k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070314,Tofacitinib Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,Digoxin,[Digoxin],2 h,,IC50,IC50,311,umol/L,"FDA approval package document: Pharmacology Review 203214/S-000 Part 04, page:18 PDF 4616k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097971,Celiprolol,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing Caco2 cells,,,Paclitaxel,,,,Ki,Ki,313,ŒºM,"Gao, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070622,"Quinidine1,2,4",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,340,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070623,Vincristine,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,345,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070624,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,350,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070034,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"CR1R12 cells, recombinant",0-500 uM,,Daunorubicin,[Daunorubicin Hydrochloride],30 min,,IC50,IC50,356,uM,JOURNAL:Pharmacological Research   PAGES:800   VOLUME:18,Literature,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070038,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.001-10 mM,,[14C]-Erythromycin,[Erythromycin],30 min,,IC50,IC50,359,uM,DOI:10.1016/j.ijpharm.2010.05.027   JOURNAL:International Journal of Pharmacology   PAGES:114   VOLUME:395,Literature,http://dx.doi.org/10.1016/j.ijpharm.2010.05.027,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097972,Dihydroergocryptine,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,360.5,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070040,Olodaterol Hydrochloride,Cl.COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Digoxin,[Digoxin],,concentration-dependent inhibition,IC50,IC50,365,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 203108/S-000, page:70 PDF 9821k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097794,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.001-10 mM,,[14C]-Erythromycin,[Erythromycin],30 min,,Ki,Ki,385.5,uM,DOI:10.1016/j.ijpharm.2010.05.027   JOURNAL:International Journal of Pharmacology   PAGES:114   VOLUME:395,Literature,http://dx.doi.org/10.1016/j.ijpharm.2010.05.027,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070043,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,394,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097795,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,400,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097973,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Vinblastine1,,,,Ki,Ki,400,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070625,Alpha-terpinene,CC1=CC=C(CC1)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,414,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070626,Tetraphenylphosphonium,C1=CC=C(C=C1)[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,LDS-751,,,,IC50,IC50,426.6,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070627,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,429,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070628,Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,430,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097856,Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0.01-0.30 umol/L,,Verapamil Hydrochloride,[Verapamil Hydrochloride],2 h,,Ki,Ki,434,umol/L,DOI:10.1124/dmd.112.049577   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:683   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.049577,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070629,"Verapamil2,4",CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Fluo-3,,,,IC50,IC50,446.5,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070630,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,472,ŒºM,"Takara, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070631,Terpinolene,CC1=CCC(=C(C)C)CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,481,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097800,Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,483.3,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097803,Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,483.3,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097974,Troleandomycin,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,483.3,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070632,Tetraphenylphosphonium,C1=CC=C(C=C1)[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,NIH-3T3-G185 cells,,,Daunorubicin,,,,IC50,IC50,490,ŒºM,"Wang, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070046,Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,500,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070051,Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,500,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070054,Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",8-300 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,500,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070633,(-)-citronellol,C[C@@H](CCC=C(C)C)CCO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,504,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097975,Dihydroergocristine,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,511,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070055,Rosuvastatin Calcium,[Ca++].CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Cells,,,5-Thio-tetramethylrosamine,[Thio-tetramethylrosamine],,,IC50,IC50,600,uM,DOI:10.1002/ijc.25295   JOURNAL:International Journal of Cancer   PAGES:2936   VOLUME:127,Literature,http://dx.doi.org/10.1002/ijc.25295,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070634,(-)-beta-pinene,CC1([C@H]2CCC(=C)[C@@H]1C2)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,"Digoxin1,3",,,,IC50,IC50,608,ŒºM,"Yoshida, 2006",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070635,Celiprolol,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,730,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097976,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing MDCK cells,,,"Digoxin1,3",,,,Ki,Ki,768,ŒºM,"Tang, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070637,Doxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,990,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097807,Dihydroergotamine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097810,Dihydroergotamine Mesylate,CS(O)(=O)=O.[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2C)C(=O)N[C@]1(C)O[C@]2(O)N([C@@H](CC3=CC=CC=C3)C(=O)N3CCC[C@@]23[H])C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097812,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097815,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097819,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097822,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],30 min,,Ki,Ki,1000,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097977,Dihydroergotamine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,1000,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097978,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,1000,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097979,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1-expressing LLC-PK1 cells,,,Calcein AM,,,,Ki,Ki,1000,ŒºM,"Ekins, 2002",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070638,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,1300,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070639,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,Calcein AM,,,,IC50,IC50,1440,ŒºM,"Eneroth, 2001",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070640,Pindolol,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,1950,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070641,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,6500,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070642,Tranylcypromine,N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,"Verapamil2,4",,,,IC50,IC50,14000,ŒºM,"Doppenshmitt, 1998",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073484,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,<10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073486,Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,<10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073488,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,<10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070067,Quinidine Gluconate,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,<5,uM,DOI:10.1128/AAC.0152710   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:1282   VOLUME:55,Literature,http://dx.doi.org/10.1128/AAC.01527-10,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070071,Quinidine Polygalacturonate,O[C@@H]([C@@H](O)[C@H](O)C(O)=O)[C@@H](O)C(O)=O.[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,<5,uM,DOI:10.1128/AAC.0152710   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:1282   VOLUME:55,Literature,http://dx.doi.org/10.1128/AAC.01527-10,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070072,Quinidine Sulfate,OS(O)(=O)=O.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,<5,uM,DOI:10.1128/AAC.0152710   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:1282   VOLUME:55,Literature,http://dx.doi.org/10.1128/AAC.01527-10,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070076,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,<5,uM,DOI:10.1128/AAC.0152710   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:1282   VOLUME:55,Literature,http://dx.doi.org/10.1128/AAC.01527-10,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070077,Methylnaltrexone Bromide,[Br-].C[N+]1(CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35)CC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.03-10 uM,,Digoxin,[Digoxin],120 min,,IC50,IC50,> 10,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 208271/S-000 Part 02, page:12 PDF 454k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070080,Talazoparib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CN1N=CN=C1[C@@H]1[C@H](NC2=C3C(=CC(F)=C2)C(=O)NN=C13)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,<=1 uM,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>1,uM,"EMA approval document: Public Assessment Report EMA/270498/2019; EMEA/H/C/004674/0000, page:52 PDF 4480k",EMA approval document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070081,Eribulin Mesylate,CS(O)(=O)=O.[H][C@@]12CC[C@@H]3CC(=O)C[C@H]4[C@H](C[C@H]5O[C@@H](CC[C@@H]6O[C@@H](CC[C@]78C[C@@]9([H])O[C@]([H])([C@@]([H])(O1)[C@@]9([H])O7)[C@@]([H])(O8)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](O)CN)[C@@H]4OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50,>10,uM,DOI:10.3109/00498254.2010.542256   JOURNAL:Xenobiotica   PAGES:320   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2010.542256,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070087,Methylnaltrexone Bromide,[Br-].C[N+]1(CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35)CC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.03-10 uM,,Digoxin,[Digoxin],,,IC50,IC50,>10,uM,"FDA approval package document: Pharmacology Review 208271/S-000 Part 02, page:16 PDF 2957k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070316,Eribulin Mesylate,CS(O)(=O)=O.[H][C@@]12CC[C@@H]3CC(=O)C[C@H]4[C@H](C[C@H]5O[C@@H](CC[C@@H]6O[C@@H](CC[C@]78C[C@@]9([H])O[C@]([H])([C@@]([H])(O1)[C@@]9([H])O7)[C@@]([H])(O8)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](O)CN)[C@@H]4OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-10 uM,,Digoxin,[Digoxin],,,IC50,IC50,>10,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201532/S-000 Part 02, page:15 PDF 853k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073490,Fluoxetine Hydrochloride,Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],,,IC50,IC50 BA/AB,>10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073492,Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@@H](OC)[C@@H](O[C@H]5C[C@@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)C(O5)[C@@H](C)CC)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073494,Mitomycin,CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],,,IC50,IC50 BA/AB,>10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073496,Procainamide Hydrochloride,Cl.CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>10,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070092,Amisulpride,CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,0.3-100 uM,,Loperamide,[Loperamide Hydrochloride],,,IC50,IC50,>100,uM,"FDA approval package document: Approval Package 209510/S-000 Part 06, page:75 PDF 14639k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070095,Amprenavir,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,>100,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070101,Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>100,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070104,Cimetidine,CN\C(NC#N)=N/CCSCC1=C(C)NC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>100,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070108,Dabrafenib Mesylate,CS(O)(=O)=O.CC(C)(C)C1=NC(=C(S1)C1=CC=NC(N)=N1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,DOI:10.1124/dmd.116.073932   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:646   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073932,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070110,Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,>100,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070114,Dolutegravir Sodium,[Na+].[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.3-100 uM,,3H-labeled digoxin,[Digoxin],90 min,,IC50,IC50,>100,uM,DOI:10.1124/dmd.112.048918   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:353   VOLUME:41,Literature,http://dx.doi.org/10.1124/dmd.112.048918,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070115,Dolutegravir Sodium,[Na+].[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,<=100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204790 Part 08, page:121 PDF 10542k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070116,Dolutegravir Sodium,[Na+].[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,<=100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204790 Part 08, page:122 PDF 10542k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070117,Dolutegravir Sodium,[Na+].[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.3-100 uM,,Digoxin,[Digoxin],90 min,,IC50,IC50,>100,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204790/S-000 Part 08, page:122 PDF 10273k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070118,Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC cells, recombinant",<=100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,DOI:10.1128/AAC.0249218   ISSN:00664804   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:e0249218,Literature,http://dx.doi.org/10.1128/AAC.02492-18,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070121,Fostemsavir Tromethamine,NC(CO)(CO)CO.COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2COP(O)(O)=O)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-100 uM,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>100,uM,"FDA approval package document: Approval Package 212950/S-000 Part 14, page:9 PDF 2384k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070123,Indinavir Sulfate,OS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2)CC1=CC=CN=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.78-50 uM,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,>100,uM,DOI:10.1128/AAC.0067107   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:3498   VOLUME:51,Literature,http://dx.doi.org/10.1128/AAC.00671-07,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070127,Losartan Potassium,[K+].CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388/ DX cells, recombinant",0-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>100,uM,DOI:10.1002/bdd.699   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:150   VOLUME:31,Literature,http://dx.doi.org/10.1002/bdd.699,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070130,Losartan Potassium,[K+].CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Caco2 cells, recombinant",,,[3H]-digoxin,[Digoxin],1 h,,IC50,IC50,>100,uM,DOI:10.1016/j.lfs.2009.11.006   JOURNAL:Life Sciences   PAGES:52   VOLUME:86,Literature,http://dx.doi.org/10.1016/j.lfs.2009.11.006,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070134,Losartan Potassium,[K+].CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",0.4-100 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>100,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070137,Naloxegol Oxalate,OC(=O)C([O-])=O.[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CC[NH+](CC=C)[C@H](C4)[C@]1(O)CC[C@@H]2OCCOCCOCCOCCOCCOCCOCCOC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,3-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204760/S-000 Part 01, page:63 PDF 15723k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070138,Naloxegol Oxalate,OC(=O)C([O-])=O.[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CC[NH+](CC=C)[C@H](C4)[C@]1(O)CC[C@@H]2OCCOCCOCCOCCOCCOCCOCCOC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCKII cells,3-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>100,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204760/S-000 Part 01, page:64 PDF 15723k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070144,Prazosin Hydrochloride,Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,>100,uM,DOI:10.3109/00498254.2011.587033   JOURNAL:Xenobiotica   PAGES:712   VOLUME:41,Literature,http://dx.doi.org/10.3109/00498254.2011.587033,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073498,Caffeine Citrate,OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1C=NC2=C1C(=O)N(C)C(=O)N2C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073500,Chlorzoxazone,ClC1=CC2=C(OC(=O)N2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073502,Colchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073504,Fexofenadine Hydrochloride,Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073506,Morphine Sulfate,O.OS(O)(=O)=O.[H][C@@]12C=C[C@H](O)[C@@H]3OC4=C(O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073508,Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.964   JOURNAL:Molecular Pharmacology   PAGES:964   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.964,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073510,Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,,,[3H]-Digoxin,[Digoxin],,,IC50,IC50 BA/AB,>100,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097823,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",,,[3H]-Pitavastatin,[Pitavastatin Calcium],,,Ki,Ki,>100,uM,DOI:10.1124/dmd.106.009290   JOURNAL:Drug Metabolism and Disposition   PAGES:1229   VOLUME:34,Literature,http://dx.doi.org/10.1124/dmd.106.009290,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073513,Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,>1000,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073515,Cimetidine,CN\C(NC#N)=N/CCSCC1=C(C)NC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,>1000,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073517,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-Digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,>1000,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073518,Paroxetine Mesylate,CS(O)(=O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,1-1000 uM,,[3H]-digoxin,[Digoxin],2 h,,IC50,IC50 BA/AB,>1000,uM,DOI:10.1021/mp900174z   JOURNAL:Molecular Pharmaceutics   PAGES:398   VOLUME:7,Literature,http://dx.doi.org/10.1021/mp900174z,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070318,Cefiderocol Sulfate Tosylate,OS(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.[H][C@]12SCC(C[N+]3(CCCC3)CCNC(=O)C3=CC=C(O)C(O)=C3Cl)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,<=10000 umol/L,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>10000,umol/L,"FDA approval package document: Approval Package 209445/S-000 Part 10, page:3 PDF 5469k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070147,Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Rhodamine 123,[Rhodamine 123],15 min,,IC50,IC50,>1174,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070320,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,125 uM,,Digoxin,[Digoxin],,,IC50,IC50,>125,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 03, page:3 PDF 1205k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070151,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MES-SA/ Dx5 cells,,,Verapamil,[Verapamil Hydrochloride],15 min,,IC50,IC50,>1714,uM,DOI:10.1016/j.ejps.2010.05.016   JOURNAL:European Journal of Pharmaceutical Sciences   PAGES:86   VOLUME:41,Literature,http://dx.doi.org/10.1016/j.ejps.2010.05.016,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070155,Deutetrabenazine,[H][C@]12CC(=O)[C@H](CC(C)C)CN1CCC1=CC(OC([2H])([2H])[2H])=C(OC([2H])([2H])[2H])C=C21,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.1-20 uM,,Digoxin,[Digoxin],,,IC50,IC50,>20,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 208082/S-000 Part 03, page:21 PDF 7751k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070321,Baloxavir Marboxil,[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@]1([H])C2=C(SCC3=C1C=CC(F)=C3F)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.5-30 umol/L,,3H-labeled digoxin,[Digoxin],2 h,,IC50,IC50,>20.9,umol/L,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 210854/S-000 Part 02, page:4 PDF 355k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070160,Eprosartan Mesylate,CS(O)(=O)=O.CCCCC1=NC=C(N1CC1=CC=C(C=C1)C(O)=O)\C=C(/CC1=CC=CS1)C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388/ DX cells, recombinant",0-200 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>200,uM,DOI:10.1002/bdd.699   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:150   VOLUME:31,Literature,http://dx.doi.org/10.1002/bdd.699,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070161,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"Cells, recombinant",2-200 uM,,Deuterated quinidine,[Quinidine Sulfate],,,IC50,IC50,>200,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204441/S-000 Part 02, page:13 PDF 383k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097827,Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1N=CNC2=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097831,Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097832,Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097835,Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097838,Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097841,Zidovudine,CC1=CN([C@H]2C[C@H](N=N#N)[C@@H](CO)O2)C(=O)NC1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",,,Calcein AM,[Calcein acetomethoxy ester],0-30 min,,Ki,Ki,>2000,uM,DOI:10.1248/bpb.23.1528   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1528   VOLUME:23,Literature,http://dx.doi.org/10.1248/bpb.23.1528,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070164,Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070165,Benzbromarone,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=CC=CC=C2O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070167,Dicumarol,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070168,Dicumarol,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070169,Fostemsavir Tromethamine,NC(CO)(CO)CO.COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2COP(O)(O)=O)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.1-25 uM,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>25,uM,"FDA approval package document: Approval Package 212950/S-000 Part 14, page:9 PDF 2384k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070170,Loxapine,CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070171,Loxapine,CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070172,Loxapine Hydrochloride,Cl.CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070173,Loxapine Hydrochloride,Cl.CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070174,Loxapine Succinate,OC(=O)CCC(O)=O.CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070175,Loxapine Succinate,OC(=O)CCC(O)=O.CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070177,Mifepristone,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@@]1(O)C#CC)C1=CC=C(C=C1)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070179,Niclosamide,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)N(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070181,Pimozide,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070182,Pimozide,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070184,Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Jurkat cells,,,JC1,[JC-1],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070187,Verapamil Hydrochloride,Cl.COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,CCRF-CEM/ ADR5000 cells,,,Calcein AM,[Calcein acetomethoxy ester],15 min,,IC50,IC50,>25,uM,DOI:10.1089/adt.2007.107   JOURNAL:Assay and Drug Development Technologies   PAGES:263   VOLUME:6,Literature,http://dx.doi.org/10.1089/adt.2007.107,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070188,Fostemsavir Tromethamine,NC(CO)(CO)CO.COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2COP(O)(O)=O)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",1-250 uM,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>250,uM,"FDA approval package document: Approval Package 212950/S-000 Part 14, page:9 PDF 2384k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070190,Guanabenz Acetate,CC(O)=O.NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,>250,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070195,Propranolol Hydrochloride,Cl.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,K562 cells,0.08-100 uM,,Calcein AM,[Calcein acetomethoxy ester],8 min,,IC50,IC50,>250,uM,DOI:10.1007/s0021083450   JOURNAL:NaunynSchmiedeberg's Archives of Pharmacology   PAGES:11   VOLUME:379,Literature,http://dx.doi.org/10.1007/s00210-008-0345-0,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE073519,Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0-250 uM,,[3H]-Talinolol,[Talinolol],0-120 min,,IC50,IC50 BA/AB,>250,uM,DOI:10.1211/0022357043969   JOURNAL:Journal of Pharmacy and Pharmacology   PAGES:967   VOLUME:56,Literature,http://dx.doi.org/10.1211/0022357043969,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070196,Deutetrabenazine,[H][C@]12CC(=O)[C@H](CC(C)C)CN1CCC1=CC(OC([2H])([2H])[2H])=C(OC([2H])([2H])[2H])C=C21,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Caco2 cells,0.01-3 uM,,Digoxin,[Digoxin],,,IC50,IC50,>3,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 208082/S-000 Part 03, page:13 PDF 7751k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070197,Dabrafenib Mesylate,CS(O)(=O)=O.CC(C)(C)C1=NC(=C(S1)C1=CC=NC(N)=N1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.3-100 uM,,Digoxin,[Digoxin],,,IC50,IC50,>30,uM,DOI:10.1124/dmd.116.073932   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:646   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073932,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070198,Talazoparib Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.CN1N=CN=C1[C@@H]1[C@H](NC2=C3C(=CC(F)=C2)C(=O)NN=C13)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,<=30 uM,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>30,uM,"EMA approval document: Public Assessment Report EMA/270498/2019; EMEA/H/C/004674/0000, page:52 PDF 4480k",EMA approval document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070322,Lenvatinib Mesylate,CS(O)(=O)=O.COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,3H-Digoxin,[Digoxin],,,IC50,IC50,>30,umol/L,"EMA approval document: Assessment Report EMA/250082/2015; EMEA/H/C/003727/0000, page:29 PDF 3635k",EMA approval document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070323,Lenvatinib Mesylate,CS(O)(=O)=O.COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,LLC-PK1 cells,,,3H-labeled digoxin,[Digoxin],,,IC50,IC50,>30,umol/L,"EMA approval document: Assessment Report EMA/578759/2016; EMEA/H/C/004224/0000, page:35 PDF 2684k",EMA approval document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097847,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,Vinblastine,[Vinblastine Sulfate],1 h,,Ki,Ki,>400,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE097848,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",,,[3H]-vinblastine,[Vinblastine Sulfate],,,Ki,Ki,>400,uM,DOI:10.1124/mol.61.5.974   JOURNAL:Molecular Pharmacology   PAGES:974   VOLUME:61,Literature,http://dx.doi.org/10.1124/mol.61.5.974,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070199,Cimetidine,CN\C(NC#N)=N/CCSCC1=C(C)NC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070203,Colchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070205,Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070209,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070213,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070215,Etoposide,[H][C@@]12CO[C@@H](C)O[C@@]1([H])[C@H](O)[C@@H](O)[C@H](O[C@@H]1C3=C(C=C4OCOC4=C3)[C@@H](C3=CC(OC)=C(O)C(OC)=C3)[C@@]3([H])C(=O)OC[C@]13[H])O2,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070217,Hydrocortisone,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070220,Midazolam Hydrochloride,Cl.CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=CC(Cl)=CC=C3N12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070224,Morphine Sulfate,O.OS(O)(=O)=O.[H][C@@]12C=C[C@H](O)[C@@H]3OC4=C(O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070227,Ranitidine Hydrochloride,Cl.CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070229,Vinblastine Sulfate,OS(O)(=O)=O.[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@H]2C[N@](CCC3=C1NC1=CC=CC=C31)C[C@](O)(CC)C2)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"L-MDR1 cells, recombinant",0.05-50 uM,,Calcein AM,[Calcein acetomethoxy ester],45 min,,IC50,IC50,>50,uM,DOI:10.1021/jm021012t   JOURNAL:Journal of Medicinal Chemistry   PAGES:1716   VOLUME:46,Literature,http://dx.doi.org/10.1021/jm021012t,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070643,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070644,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070645,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070646,Colchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070647,Colchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070648,Colchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070649,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070650,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070651,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070652,Digoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070653,Digoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070654,"Digoxin1,3",C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070658,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070659,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070660,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070661,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070662,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070663,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070664,Hydrocortisone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070665,Hydrocortisone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070666,Hydrocortisone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070667,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070668,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070669,Morphine,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070670,Morphine,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070671,Morphine,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070672,Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070673,Ranitidine,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070674,Ranitidine,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070675,Ranitidine,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070676,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070677,Saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070678,Saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1b expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070679,Vinblastine,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,Mouse mdr1a expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070680,Vinblastine1,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDR1 expressing LLC-PK1 cells,,,Calcein AM,,,,IC50,IC50,>50,ŒºM,"Schwab, 2003",UCSF-FDA,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070233,Olmesartan Medoxomil,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=O)OC1=C(C)OC(=O)O1)C(C)(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"P388/ DX cells, recombinant",0-500 uM,,Calcein AM,[Calcein acetomethoxy ester],60 min,,IC50,IC50,>500,uM,DOI:10.1002/bdd.699   JOURNAL:Biopharmaceutics and Drug Disposition   PAGES:150   VOLUME:31,Literature,http://dx.doi.org/10.1002/bdd.699,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070236,Aliskiren Hemifumarate,OC(=O)\C=C\C(O)=O.COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070238,Aliskiren Hemifumarate,OC(=O)\C=C\C(O)=O.COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070239,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070241,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070243,Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070246,Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070249,Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070250,Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070251,Diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070253,Diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070255,Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070257,Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070260,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070262,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070263,Fexofenadine Hydrochloride,Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070265,Fexofenadine Hydrochloride,Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070269,Galantamine Hydrobromide,Br.COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070270,Galantamine Hydrobromide,Br.COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070271,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070274,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070276,Propantheline Bromide,[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=C(OC3=C1C=CC=C3)C=CC=C2)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070278,Propantheline Bromide,[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=C(OC3=C1C=CC=C3)C=CC=C2)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070279,Ramelteon,CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070282,Ramelteon,CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070283,Ranitidine Hydrochloride,Cl.CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070284,Ranitidine Hydrochloride,Cl.CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070289,Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070290,Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070293,Scopolamine,CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,Digoxin,[Digoxin],2.5 h,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070294,Scopolamine,CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"LLC-PK1 cells, recombinant",0-60 uM,,[Lucifer yellow],[Lucifer yellow],,,IC50,IC50,>60,uM,DOI:10.1002/jps.22652   JOURNAL:Journal of Pharmaceutical Sciences   PAGES:4013   VOLUME:100,Literature,http://dx.doi.org/10.1002/jps.22652,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070295,Daclatasvir Dihydrochloride,Cl.COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,MDCK-MDR1 cells,0.1-10 uM,,[3H] Digoxin,[Digoxin],,,IC50,IC50,>7,uM,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206843/S-000, page:323 PDF 31325k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE070296,Dabrafenib Mesylate,CS(O)(=O)=O.CC(C)(C)C1=NC(=C(S1)C1=CC=NC(N)=N1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vitro,Cell line,"MDCKII cells, recombinant",0.08-80 uM,,Digoxin,[Digoxin],,,IC50,IC50,>80,uM,DOI:10.1124/dmd.116.073932   ISSN:00909556   JOURNAL:Drug Metabolism and Disposition   PAGES:646   VOLUME:45,Literature,http://dx.doi.org/10.1124/dmd.116.073932,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure